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SUMMARY
Diabetes mellitus carries a twenty-fold excess mortality for insulin-dependent (IDDM) 
and two-fold for non-insulin dependent (NIDDM) patients compared with the non­
diabetic population. Almost all of this excess is confined to those people who develop 
persistent proteinuria and is due mainly to cardiovascular and renal disease. In insulin- 
dependent diabetes, uraemia is common, whilst in non-insulin dependent diabetes, 
cardiovascular disease accounts for the majority of deaths. Once persistent proteinuria 
develops, progression of IDDM patients to end-stage renal disease is inevitable.
The dip-stick tests classically used to detect proteinuria are insensitive. Sensitive 
immunoassay techniques have shown that urine from healthy subjects normally contains 
<20 mg album in/1. There is thus a large gap between the norm al range and 
pathological proteinuria detected by conventional testing. Diabetic patients may 
excrete more albumin than normal subjects, but remain dip-stick negative - so called 
microalbuminuria. Several studies have shown that those IDDM patients with 
microalbuminuria are the ones who progress to persistent proteinuria, whilst in non­
insulin-dependent diabetes, similar levels of albumin excretion are predictive of early 
death, mainly from cardiovascular disease. The cut-off point of microalbuminuria 
predicting increased risk is 30^ug/min in a timed overnight urine collection.
A sensitive radioimmunoassay for urinary albumin has been established and validated. 
The albumin excretion rate (AER) in timed overnight samples in 106 healthy adults 
was 5.4 (1.7-10.5)/Ug/min (geometric mean and range). The excretion rate was higher 
in males than females [5.8(2.0-11.2) v 3.6(1.4-9.3) ^ g/m in; p<0.005]. No influence of 
age on AER was seen. In 64 healthy children mean age 9 years (range 3-17), AER 
was significantly lower than in the adult population [2.5(0.6-7.0)^jg/min; p<0.001]. 
Excretion rates were similar in boys and girls, but AER correlated with age fr*=0.33,
p<0.001).
AER was measured in 940 unselected diabetic patients, 416 IDDM and 524 NIDDM. 
Seventy one percent had AER in the normal range, 15% had AER between 10.6-29.9 
^g/m in , 8.4% 30-150 ^g/m in and 5.5% >150 ^jig/min. The mean AER was higher in 
the NIDDM patients (p<0.01) and the proportion of NIDDM patients with abnormal 
rates of albumin excretion was higher than in IDDM (p<0.002). Univariate analysis 
showed that in IDDM, AER was related to known duration of diabetes (r=0.21,
12
p<0.001), systolic BP (r=0.18, p<0.001), male sex (t=2.46, p<0.002) and the presence of 
retinopathy (t=4.61, p<0.001), peripheral vascular disease (t=2.85, p<0.01) and 
peripheral neuropathy (t=2.50, p<0.02). On multiple regression analysis the presence of 
retinopathy and male sex remained significant (r=0.28, p<0.001).
In NIDDM, AER correlated with known duration of diabetes (r=0.18, p<0.01), systolic 
(r=0.20, p<0.001) and diastolic blood pressure (r=0.17, p<0.001) and to the presence of 
peripheral vascular disease (t=4.12, p<0.001), retinopathy (t=3.66, p<0.001) and 
ischaemic heart disease (t=2.64, p<0.002). On multiple regression analysis, systolic 
blood pressure, peripheral vascular disease and retinopathy remained significant 
(r=0.31, p<0.001). In IDDM, only one patient with duration of diabetes less than 5 
years had AER 30-150 ^ jug/min, whereas this level was observed at all durations of 
NIDDM, presumably because of the long silent phase of NIDDM.
Albumin excretion was measured in 68 children with insulin-dependent diabetes, with 
mean duration of diabetes 3.8 (range 1-13) years. AER was similar to that of non­
diabetic children [2.5(0.7-9.5) v 2.4(0.2-20.8) ^ g/m in] and correlated with age (H=0.36, 
p<0.001). When matched for age, there was no difference in AER between diabetic 
boys and girls [3.1 (0.9-9.5) v 2.3(1.1-7.5)^g/min].
Day-to-day variation in albumin excretion is high. In 8 healthy adults, the coefficient 
of variation (CV) of AER measured on 9.4 (range 7-11) occasions over 6 weeks, was 
13.1%. In diabetic patients the CV was 47.2% in those with normal AER, 17.0% in 
microalbuminuric patients and 10.5% in those with persistent proteinuria. During 
follow-up for at least 18 months the mean rate of change of AER was +11.3(-31.4 - 
+105.5)% per year in normoalbuminuric patients and +1.3(-44.4 - +101.8)% per year in 
microalbuminuric patients. Several patients showed large fluctuations in AER.
The predictive power of microalbuminuria is based on albumin excretion rates 
measured in timed urine collections, which are impractical and open to many sources 
of error. Measurement of albumin concentration on an aliquot of overnight urine had 
poor sensitivity and specificity in identifying those patients with AER 30-150 ug/min. 
However, correction for creatin ine excretion im proved the value of the test 
considerably. Thus, an albuminrcreatinine ratio >3.5 had a sensitivity of 98% and 
sp ec ific ity  of 69% in p red ic ting  AER 30-150 ^ug/m in . M easurem ent of
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albumin:creatinine ratio in an aliquot of the first morning urine may thus be an 
acceptable screening test for microalbuminuria.
It is likely that the detection and monitoring of abnormal albumin excretion will 
become routine in the diabetic clinic. Microbumintest is a commercial reagent tablet 
which the m anufacturers claim will detect albumin concentrations >40^ug/ml. 
Evaluation of the tablet by 1 operator using 106 urine samples [albumin concentration 
34.5(1.5-149) ^ iug/ml; mean (range)] revealed a sensitivity of 84% and specificity 80%. 
Eight operators tested 24 urine samples twice. There was a large intra- and inter­
operator variability. This variability, plus the low sensitivity and specificity, make 
Microbumintest unsuitable for routine use.
Urin-Pak is a commercially marketed, automated immunoturbidimetric method of 
albumin measurement. When compared with an in-house radioimmunoassay, the 
overall correlation was good (r=0.91, y= 1.02X4-0.078), precision satisfactory (intra- and 
inter-assay CV at albumin concentration of 40.7 ^ g /m l, 5.2%) and the method proved 
easy and quick to use. However, 28% of the samples lay outwith ±20% of the line of 
identity.
The hallm ark  of d iabetic  neph ropa thy  is the accum ulation  o f abnorm al 
mucopolysaccharide material in the mesangium and basement membrane. The 
mucolytic agent bromhexine decreases glomerular volume in experimental diabetes and 
also decreases the u rinary  excretion of m ucopolysaccharides in IDDM. In a 
randomised, double-blind, placebo-controlled trial, bromhexine 72 mg daily had no 
e ffe c t on a lbum in excre tion  in IDDM p a tien ts  w ith  n o rm o alb u m in u ria , 
microalbuminuria and persistent proteinuria.
Growth factors may be involved in diabetic renal hypertrophy. The role of epidermal 
growth factor (hEGF) has been examined. Albumin and hEGF excretion were 
measured in 19 healthy adults with normal albumin excretion and 55 diabetic subjects 
with AER 1.4-879^jug/min. The hEGF:creatinine ratio was decreased in the diabetic 
subjects with abnormal albumin excretion. There was a significant correlation between 
hEGF:creatinine and AER (r=-0.49, p=0.02).
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Thus abnormal albumin excretion is common in diabetes and reflects widespread 
vascular disease. Identification of patients with abnormal excretion by frequent testing 
over many years, coupled to aggressive management of the associated abnormalities, 
may lead to diminution of the excess mortality carried by these patients.
15
CHAPTER 1 
Introduction
1.1 The excess mortality associated with diabetes mellitus
It was not until many years after the introduction of insulin treatment for diabetes 
mellitus in 1922 that the full ravages of the long-term  complications of diabetes 
became clear(l,2,3,4,5). In 1953 Lundbaek published the results of a survey of 234 
patients who were found to have diabetes between 1924 and 1934 and who had 
survived for at least 15 years (1). Thirty percent had died, the common causes of 
death being heart disease, cerebrovascular disease and renal insufficiency. Significant 
numbers of survivors had evidence of retinopathy, nephropathy and coronary and 
peripheral vascular disease. Lundbaek concluded tha t the various long-term  
manifestations of diabetes were different expressions of a generalised, specific diabetic 
vascular disease.
In a study of 317 Danish patients diagnosed diabetic before the age of 31 years and 
before 1933, the mortality rate after 40 years of diabetes was 2-6 times that of an age 
and sex matched non-diabetic population(5). Uraemia was the cause of death in 31% 
of cases and myocardial infarction in 25%. In an American study of 1966 children 
found to have insulin-dependent diabetes (IDDM) before the age of 17 years, and 
diagnosed between 1950 and 1981, a sevenfold excess in mortality was found(6). After 
the age of 20, the annual mortality rate was 20 times that of the non-diabetic 
population. The cause of death was renal disease in almost 40%, with cardiovascular 
disease accounting for a further 10%. A UK survey of deaths occurring during 1979 
in diabetic patients under the age of 50 years, found that 15% of 447 deaths were from 
nephropathy(7). In those patients diagnosed before the age of 31 years, almost equal 
numbers died of renal and cardiac disease which together accounted for over half the 
deaths. Death in IDDM patients with nephropathy is attributed to renal failure in 
approximately 60% and cardiovascular causes in 24-36% (7,8,9).
In non-insulin dependent diabetes (NIDDM), such clear-cut data is not available, but 
several studies have found an overall mortality rate of twice that of the non-diabetic 
population(3,10). The major cause of death is cardiovascular disease, being responsible 
fo r 60% of deaths, w ith  renal disease accounting  fo r only re la tiv e ly  few  
deaths(10,ll,12). In the USA, the relative risk of renal mortality in diabetic patients 
aged over 45 years is doubled, compared with the twenty-fold excess seen in those
16
under 45 years(13). In the UK in 1983-84, 24% of the diabetic patients accepted for 
renal replacement therapy had not been treated with insulin(14). Thus, although the 
risk to the individual patient is small, because of the high prevalence of NIDDM, the 
number of patients with NIDDM who may potentially develop diabetic nephropathy is 
large.
Thus both IDDM and NIDDM carry a considerable risk of early mortality, particularly 
from renal and cardiovascular disease. In IDDM, renal disease predominates, whilst in 
NIDDM, cardiovascular disease is more common.
1.2 Proteinuria and excess mortality
The importance of proteinuria was recognised early. In 1936 Kimmelstiel and Wilson 
described 8 patients with the clinical syndrome of oedema of the nephrotic type, renal 
decompensation, hypertension and large quantities of albuminuria, who at autopsy had 
the classical histological features of diabetic nephropathy(15). In a very large study of 
1465 autopsies performed on diabetic subjects, Bell highlighted the importance of 
severe p ro te inuria  in suggesting the presence of advanced glom erular lesions, 
particularly in young subjects(16). The importance of proteinuria as a predictor of 
excess total mortality and not only of renal disease has been demonstrated in several 
studies. In the Danish study of young patients diagnosed before 1933, the excess 
mortality among patients who developed persistent proteinuria within 40 years of 
diagnosis of diabetes was 3-4 times higher than in patients who did not have 
proteinuria after 40 years(5). In the cohort diagnosed before 1953, proteinuria 
developed in 41%(8). After 40 years of diabetes, only 10% of those who developed 
persistent proteinuria were alive, whereas more than 70% who did not develop 
proteinuria survived. In an almost identical group of patients, Borch-Johnsen showed 
that the relative mortality in those without proteinuria remained constant at about 2, 
whilst for those with proteinuria, there was a dramatic increase in relative mortality to 
a maximum of 100 at age 35 years(17). Conversely, in a group of 92 patients who had 
had diabetes for more than 40 years, only 8 had proteinuria(18).
It would thus seem that in IDDM proteinuria is a marker for those patients at increased 
risk of early death from both renal and cardiovascular causes. The significance of 
proteinuria is less well studied in NIDDM, although in a small study an excess 
mortality was found in those with marked proteinuria(19).
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1.3 The inevitable progression from persistent proteinuria to end-stage renal failure
In IDDM, once persistent proteinuria develops, the decline in renal function is 
relentless, the interval to end-stage renal failure averaging 7-10 years with a range of 
1-25 years(8,9,20,21). No therapeutic intervention yet tried has halted or reversed the 
decline. All patients with declining renal function have hypertension(7,9,20,22) and 
patients with persistent proteinuria but normal serum creatinine have significantly 
higher blood pressures than matched diabetic patients with normal albumin excretion 
and normal controls(23). Elevated blood pressure may accelerate the decline in renal 
function in animals(24) and in man(25). Antihypertensive therapy (B-blocker, 
diuretic, hydrallazine) has been shown to decrease the rate of decline of glomerular 
filtration rate (GFR) but not to halt the progression(26,27,28,29).
Improved blood glucose control using continuous subcutaneous insulin infusion (CSII) 
was tried for up to 24 months in 6 patients with persistent proteinuria, with no effect 
on the mean rate of decline of GFR or fractional clearance of albumin(30). However, 
numbers were small, blood glucose control although improved was not normalised, and 
there was considerable variation in response between patients. Thus whilst a dramatic 
effect on the decline in GFR probably does not occur with improving blood glucose 
control, a small effect in individual patients may have been missed. At the slightly 
earlier stage of intermittent proteinuria, improved blood glucose control has also been 
demonstrated to have no effect on GFR, although this study was marred by the wide 
variation in albumin excretion rates in the patients studied(31).
Dietary protein restriction has also been studied as a means of slowing the decline in 
renal function. In animals(32,33) and in normal man(34,35) protein ingestion increases 
GFR. It has been suggested that hyperfiltration may be involved in the pathogenesis 
of renal disease(36) and that a raised GFR may predict the future development of 
diabetic nephropathy(37). An acute (3 week) trial of protein restriction (to around 
40g/day) in patients with diabetic nephropathy showed a fall in the fractional clearance 
of albumin and IgG but no change in GFR(38). However, preliminary reports on a 
long-term (> 1 year) study suggest that decreased dietary protein intake to around 
45g/day in IDDM patients may reduce the rate of decline of GFR significantly(39).
Thus it is clear that after the development of persistent proteinuria, the decline to end- 
stage renal failure is relentless, intervention at best only slowing the rate of decline. 
Whether it is possible to alter the risk of cardiovascular disease also carried by patients
18
with persistent proteinuria has not been studied but it seems unlikely that at this 
advanced stage any dramatic effect would be seen. Prevention of diabetic nephropathy 
and perhaps also cardiovascular disease must thus take place at an earlier stage of 
diabetes, before the development of persistent proteinuria. The problem of how to 
identify those patients who would later develop proteinuria then arose.
1.4 Microalbuminuria
Persistent proteinuria as described above is generally defined as the excretion of more 
than 0.5g protein/24h in at least 3 consecutive urine samples collected over 1 year. 
Testing for protein has been by semiquantitative means with poor sensitivities such as 
dip-stick testing (Albustix, Ames Limited, Stoke Poges, Slough, UK) or by crude 
laboratory techniques such as the sulphosalicylic acid test. In 1963, Keen and 
Chlouverakis described a sensitive radioimmunoassay for urine albumin measurement 
(40). They later demonstrated that in a 2h ambulant period, the mean albumin 
excretion was 3.4mg in normal controls and significantly higher at 4.9mg in newly 
diagnosed diabetic subjects, mainly NIDDM(41). A similar elevation in albumin 
excretion rate (AER) was seen in 5 newly diagnosed IDDM patients, the AER falling 
to normal 14 days after the start of insulin treatment(42). In this same paper, AER 
was measured in 22 IDDM patients without persistent proteinuria, with duration of 
diabetes ranging from 1-40 years. Daytime AER ranged from 3.9-96.3^ g /m in , 
compared with a reference range of 5.8-22.6 ^ug/min (42). In IDDM patients with a 
short duration of diabetes, Parving showed a significant rise in AER after withdrawal 
of insulin therapy(43). In another group of 80 non-proteinuric IDDM patients with 
diabetes duration 1-39 years, elevated AER was found in 41%(44). It was thus 
obvious that diabetic subjects without persistent proteinuria could exhibit increased 
albumin excretion above the normal range. Such a level of albumin excretion has been 
called microalbuminuria.
The full significance of microalbuminuria was revealed in 1982 when several studies 
were published describing the fate of those patients who had previously shown elevated 
levels of albumin excretion. In 1966-67, the Guy’s Hospital group measured overnight 
AER in 87 IDDM patients without persistent proteinuria. At follow-up 14 years later, 
information on 63 of the original cohort was available. Of the 8 who initially had an 
AER >30^lg/min, 7 had developed persistent proteinuria and 3 (37.5%) were dead. Of 
those with an initial AER <30 jig/m in, 2 out of 55 had developed proteinuria and 5
19
(9.1%) were dead(45). It thus appeared that an AER >30^ug/min was predictive of 
persistent proteinuria and increased mortality. Several papers confirming this report 
quickly followed(37,46,47). They are summarised in Table 1. Although the types of 
urine collection, albumin assay, length of follow-up and cut-off for AER are different 
in each study, the conclusion in each paper is similar, ie that IDDM patients with an 
AER above a certain level are those who will later develop persistent proteinuria. 
Overall, of the 37 patients with an initially "high" AER, 32 developed persistent 
proteinuria, whilst only 7 of 163 with initial "low" AER progressed.
et al
These observations were later extended to NIDDM patients. Jarrett£studied 42 NIDDM 
patients, with urine negative to Albustix, initially in 1966-67 and again in 1980. Of 
the 25 survivors, 24 had initial AER <10 ug/min, whilst of the 17 deceased, 6 had 
initial AER >31 ^lg/min and 10 >10 ^ ig/min(48). The mortality risk for subjects with 
AER >31 or >10^ug/min was 3.3 and 4.0 respectively. In a larger study with a 10 year 
follow -up, the increased mortality of NIDDM patients with an initial albumin 
concentration of 30 ^ig/ml in a morning urine sample was confirmed and shown to be 
due mainly to cardiovascular disease(19). In this study, these patients were also at risk 
of progression to persistent proteinuria.
It would thus seem that in both IDDM and NIDDM, increased albumin excretion above 
normal but not yet in the Albustix-positive range carries a risk of progression to 
persistent proteinuria and also of early death from cardiovascular disease in NIDDM. 
It is noteworthy that in several papers, there is a group of diabetic subjects with AER 
clearly elevated above normal but who have not been shown to be at risk(37,45,47). 
Thus in the Guy’s Hospital paper, those patients with AER 12-29.9 ^ug/min have 
albumin excretion outwith the normal range but have not been included in the at-risk 
group(45). The different levels of AER used to divide the groups in the 6 papers 
described above indicate that the precise level of AER at which the risk is increased is 
unclear; nor are the best methods of determining AER e.g. type of urine collection, 
albumin assay methods, understood. The follow-up period in the studies ranged from 
6-14 years. H ence we have no clear idea of the ra te  o f p rog ression  of 
microalbuminuria to persistent proteinuria. Despite these deficiencies, we now appear 
to have a reliable means of identifying much earlier in the course of their disease, 
those patients at increased risk of diabetic nephropathy and early death. This 
observation opens the way to trials of therapeutic intervention at an early stage.
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1.5 Albumin excretion in normal subjects
In most papers describing abnormal albumin excretion in the diabetic population, 
comparison has been made with only small numbers of normal subjects(42,44,46). 
Only in the Bedford study were large numbers of non-diabetic subjects investigated 
but here albumin excretion was measured in a very special situation, during a 50g oral 
glucose tolerance test with the subjects remaining am bulant(41). It is obviously 
im portant to establish reference ranges for AER in a large population of normal 
subjects under standard conditions of urine collection and laboratory analysis, and to 
examine the effect of age and sex on AER. AER has been measured in 106 normal 
adults and 64 children. The results are given in Chapter 3.
1.6 Comparison of the prevalence and associated features of abnormal albumin 
excretion in insulin-dependent and non-insulin dependent diabetes
Identification of those patients at risk of early death or of end-stage renal disease is 
obviously important to allow therapeutic intervention and also to allow more accurate 
planning for facilities for later treatment. The initial work on microalbuminuria was 
done in departments with a declared interest in diabetic nephropathy, so no reliable 
figures as to the prevalence of m icroalbuminuria in an unselected population are 
available. Additionally, the prevalence of microalbuminuria in IDDM and NIDDM has 
not been compared.
Although several studies have reported a very high incidence of persistent proteinuria 
in IDDM(6,8,17) and NIDDM(49), the current prevalence of persistent proteinuria in 
the UK diabetic population seems very variable. In a large study of an apparently 
unselected out-patient population, only 2.7% had proteinuria exceeding 0.2g/24h(50). 
However, in another study of insulin-treated patients, 9.4% had persistent proteinuria 
by Albustix testing and 5.2% intermittent proteinuria(51). Although these 2 studies 
cannot be strictly compared, the large difference warrants further investigation.
As we have already seen, blood pressure is already elevated at the stage of persistent 
proteinuria with normal serum creatinine concentration(23) and hypertension is a well- 
recognised feature of end-stage renal disease(7,20,22). It is thus of interest to 
determine the blood pressure level in patients with microalbuminuria.
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Retinopathy(7,20) hypertension (7,20,22,23) and male sex(8,12,17) have long been 
associated with end-stage renal disease in IDDM. Whether these features are also seen 
in nephropathy in NIDDM is unclear. It would also be of interest to know if these 
associations are seen in patients with microalbuminuria. As the relative risks of renal 
and cardiovascular disease in IDDM and NIDDM patients with microalbuminuria 
appear to be d iffe ren t it m ight be expected tha t the features associated with 
microalbuminuria in the 2 types of diabetes might be different.
In chapter 4, the prevalence of the various degrees of albuminuria in an unselected 
clinic population of NIDDM and IDDM have been compared and the relationship of 
albumin excretion to age, sex, duration of diabetes, blood pressure and the presence of 
the other complications of diabetes explored.
1.7 Albumin excretion in children with diabetes and its relation to clinical variables 
There have been no longitudinal studies of albumin excretion in children showing that 
those with microalbuminuria are at risk of progression to diabetic nephropathy as in 
adults. However, there seems no a priori reason why they should not be. Indeed, one 
study has suggested that relative mortality in IDDM increases with decreasing age at 
diagnosis(52). Several studies have found increased albumin excretion in diabetic as 
compared to normal children(53,54,55,56) whilst one has not(57). Additionally there 
have been discrepancies in the effect of age on albumin excretion. A comparison of 
albumin excretion rates in normal adults and children and children with diabetes may 
be of some help in deciding where the cut-off for at-risk microalbuminuria in children 
might lie.
The overnight albumin excretion rates in diabetic and normal children and in normal 
adults have been compared. The relationships of age, duration of diabetes and 
metabolic control to albumin excretion have been explored.
1.8 The dav-to-dav and longer-term variation in albumin excretion
A large number of factors are known to affect albumin excretion acutely in normal 
and d iab e tic  su b jec ts , inc lud ing  p o s tu re (4 2 ,5 4 ,5 8 ), ex e rc ise (5 9 ,6 0 ) acute 
decompensation in metabolic control(42,43), and dietary protein ingestion(61). Thus 
it seems likely that there will be a large day-to-day variation in albumin excretion
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under conditions of every day life. Although several of the studies showing that 
patients with elevated AER were at risk of nephropathy based their predictions on a 
single urine sample(45,46,47), a large day-to-day variation in albumin excretion might 
result in misclassification of individual patients and may also make interpretation of 
intervention studies d ifficu lt if  only one measurement of AER were made. The 
day-to-day  variation in AER in normal subjects and diabetic patients has been 
measured.
As has already been discussed, the rate of progression from persistent proteinuria to 
end-stage renal failure is very variable, although constant in any one patient. Little 
information is available on the rate of progression of microalbuminuria to persistent 
p ro te inuria , the in itia l predictive studies having a fo llow -up in terval of 6-14 
years(19j37,45,46,47,48).
The rate of progression is obviously important in planning any intervention trial. The 
AER has therefore been measured in IDDM patients with normal and elevated albumin 
excretion at regular intervals for several years.
1.9 Mucopolysaccharide deposition and diabetic nephropathy
The early studies of Kimmelstiel and Wilson demonstrated nodular accumulation of 
hyaline material and basement membrane thickening in the glomerulus(15). With the 
advent of the electron microscope and percutaneous renal biopsy, the classical 
histological features of diabetic nephropathy are now known to be thickening of the 
basement membrane and accumulation of basement membrane-like material in the 
mesangium(62). Accumulation of this material in the glomerular tuft reduces the 
available glomerular filtration surface, so that the GFR is highly correlated to the 
filtration surface per nephron(63). This basement membrane- like material consists of 
collagen-like glycoprotein(64) and in diabetic subjects is quantitatively abnormal, with 
a decreased content of heparan sulphate(65). Loss of the anionic heparan sulphate may 
allow enhanced passage of anionic albumin across the glomerular basement membrane 
(66).
The vinca alkaloid bromhexine is a mucolytic agent thought to alter glycoprotein 
synthesis (Shelley JH, personal communication). Bromhexine has been shown to 
decrease the urinary excretion of carbohydrate-containing substances in IDDM(67) and
24
to decrease glomerular volume and possibly basement membrane thickening in 
experimental diabetes(68). The effect of bromhexine on albumin excretion in IDDM 
patients with varying degrees of nephropathy has been studied.
1.10 Epidermal growth factor and diabetic nephropathy
It is well known that at diagnosis of insulin-dependent diabetes, kidney size and GFR 
are elevated(69,70). After insulin treatment, both fall, although not to normal levels in 
all patients. A similar increase in kidney size is seen in experimental diabetes shortly 
after induction of diabetes(71). A sustained elevation of GFR may be important in the 
development of diabetic nephropathy(37). The causes of the kidney growth and 
elevated GFR and also of the accumulation of mucopolysaccharide substances described 
earlier are unclear, but involvement of growth factors is possible.
Epidermal growth factor (EGF) which was first isolated from mouse submaxillary 
glands(72) and later from human urine(73), is a potent stimulus of the growth of 
several cell types from a variety of species(74). EGF is synthesised and excreted by 
the kidney(75,76,77). It is thus a possible candidate as a renal growth factor.
The pattern of hEGF excretion in healthy subjects and in diabetic patients with 
varying degrees of albuminuria has been examined.
1.11 Screening for microalbuminuria
Given that we now have the means of identifying those diabetic patients at risk of 
diabetic nephropathy and premature mortality, and that intervention, perhaps in the 
form of improved blood glucose control, anti-hypertensive therapy or a low protein 
diet, may decrease that risk, it is likely that screening for m icroalbum inuria will 
become appropriate. Large numbers of patients will require to be tested. Since there 
is a large day-to-day variation in albumin excretion and since we are currently 
uncertain of the natural history of microalbuminuria, screening will have to be 
repeated at regular intervals. A suitable screening test will be acceptable and 
convenient for the patient, easy for the laboratory to hand, have high sensitivity and 
specificity and be cheap and capable of handling large numbers.
Almost all of the initial papers showing the predictive power of microalbuminuria used 
timed urine collections - either overnight(45,48), 24h(46,47) or short day-tim e
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collections(37). Timed urine collections are inconvenient fo r the pa tien t and 
cumbersome for the laboratory. Errors in timing or failure to collect all the urine, 
particularly so in a diabetic patient with bladder dysfunction(78) may lead to 
inaccurate results. Compliance is likely to be poor. Timed urine collections thus do 
not appear to be suitable as a screening test.
The proteinrcreatinine ratio in an aliquot of a random(79) or first voided morning 
urine sample(80) has been shown to correlate well with 24h protein excretion in a 
variety of renal diseases with heavy proteinuria. Many diabetic patients already bring 
an aliquot of the early morning urine (EMU) to the diabetic clinic and such a sample 
would avoid the rise in albumin excretion associated with posture and exercise, which 
may be exaggerated in diabetes(81,82). The ability of the albumin concentration or 
albumin:creatinine ratio in an early morning urine sample to predict AER 30-150 
ug/min has been examined.
1.12 Biochemical tests for microalbuminuria
As described above, it is likely that screening for microalbuminuria will become a 
routine requirement for diabetic care. A side-room test, equivalent to dip-stick testing 
such as A lbustix , may be appropriate  fo r in itia l qualitative screening but for 
quantification and monitoring the effect of therapy, a sensitive, accurate, reproducible, 
cheap test capable of handling large numbers is required. Two new methods for 
detection of low amounts of urinary albumin have been evaluated. Microbumintest 
(Ames, Stoke Poges, Slough, UK) is a qualitative tablet test designed to detect 
concentrations of albumin >40^ug/ml, perhaps suitable as a screening test performed in 
the diabetic clinic. U rin-Pak (Ames, Stoke Poges, Slough, UK) is an automated 
immunoturbidimetric test designed for laboratory use.
1.13 Aims and oblectives of this work
The aims and objectives of the work described in this thesis were, therefore, to:
1. Establish and validate a sensitive assay for measurement of urine albumin.
2. Determine the reference range of albumin excretion in normal adults and 
children and to examine the effects of age and gender on albumin excretion.
3. Determine the prevalence and associated features of abnormal albumin excretion 
in insulin-dependent and non-insulin dependent diabetic patients.
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4. Determine the prevalence and associated features of abnormal albumin excretion 
in children with IDDM.
5. Examine the day-to-day and long-term  variability in albumin excretion in 
diabetic subjects.
6. Evaluate the albumin:creatinine ratio measured in an early morning urine sample 
as a predictor of microalbuminuria.
7. Evaluate the commercially-produced kits, Microbumintest and Urin-Pak, for 
measurement of urinary albumin.
8. Investigate the effect of the mucolytic agent bromhexine on all levels of albumin 
excretion in IDDM.
9. Investigate the relationship of excretion of epidermal growth factor to albumin 
excretion in diabetic patients and normal subjects.
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CHAPTER 2 
GENERAL METHODS 
2.1. Albumin Assay
Urine albumin was measured by sensitive radioimmunoassay by a modified method of 
Christensen and Orskov(83).
a) Iodination
The iodination reaction was carried out in 0.05M sodium dihydrogen phosphate buffer 
(Na.H2.PO4.H2O), pH 7.5. Human serum albumin, 250jag  in 10yUl, and freshly 
prepared chloramine T, 1 0 in 10^ ul, were added to a vial containing 2 mCi 
After mixing gently for 30 s, the reaction was halted by the addition of 40 ^ ig in 400 
^ul sodium metabisulphite. The reaction products were immediately applied to a 1 by 
50cm column containing Ultragel AcA 44 (LKB, Bromma, Sweden). Elution was by 
0.04M sodium dihydrogen phosphate buffer, pH 8.0, containing 0.2% (w/v) bovine 
serum albumin (PbB). Approximately 2 ml fractions were collected and lO^ jul aliquots 
counted for 30 s on an NE1600 m ulti-well gamma counter (Nuclear Enterprises, 
Edinburgh, UK).
Fractions containing bound iodine were pooled for use in the radioimmunoassay (stock 
labelled albumin). From the total number of counts in the albumin peak and in the 
free iodine peak, the specific activity of the labelled albumin and the percent 
bound were calculated thus:
%incorporation = total counts albumin peak_______ x 100
total counts albumin peak + free *^1
Specific activity = %incorporation x 2 x 1_ uCi/^ug albumin
100 250
The incorporation was generally >90%, with specific activities of 6- 8^iCiy/jig albumin. 
A typical elution profile of the counts in each fraction is shown in Figure 1. The peak 
at fraction 31 represents bound to albumin and fractions 30 and 31 were pooled to 
form the stock labelled albumin solution. The shoulder on this peak (fraction 26) 
represents bound to altered albumin and the peak at fraction 57 free ^ 1 .
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Figure 1. Albumin iodination. Separation of 125I albumin (peak at fraction 31) 
from 12^I altered albumin (fraction 26) and free 12^I (peak at fraction 
57)
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b) Albumin Assay Protocol
The assay was carried out in PbB buffer, pH 8.0. Human serum albumin standards 
were prepared from 10% human serum albumin (Kabi Diagnostica, Stockholm, Sweden) 
in concentrations of 0.1-10^g/ml. Stock labelled albumin was diluted lO^ jul in 6 ml to 
reduce the activity to approximately 30,000 cpm in each tube. Rabbit anti-human 
albumin immunoglobulin (Dako, Copenhagen, Denmark) was diluted in PbB to a 
predetermined titre (see antibody binding curve). To 5 buffer,  standard or sample 
were added 100jal diluted label and 1 0 0 diluted antibody. After mixing, the reaction 
was incubated at 4°C for 18 hours. Precipitation of bound label was by addition of 
500 ul polyethylene glycol 6000, 25% (w/w) in assay buffer and 100j \ \  donor calf 
bovine serum (Flow Laboratories, Irvine, Ayrshire, UK). The tubes were mixed and 
then centrifuged at 2400 rpm at 4°C for 50 minutes. The supernatant was decanted 
and the precipitate counted on a Packard Auto-Gamma 5780 gamma counter (Packard, 
Pangbourne, Berkshire, UK). Total counts in each reaction tube were estimated by 
counting 100 label only. N on-specific binding was assessed by precipitated 
radioactivity in reaction tubes containing 100^1 assay buffer PbB instead of antibody. 
The binding of label to antibody was checked by inclusion of an "excess" reaction 
containing 100^1 antibody of titre 1:320 instead of diluted antibody.
N on-specific binding was 5-10% and "excess" binding 92-99% throughout. New 
labelled albumin was produced every 3 months, or earlier if the non-specific binding 
rose >10% or "excess" binding fell to <90%. Each standard and unknown was assayed 
in triplicate.
A typical albumin standard curve is shown in Figure 2. The sensitivity of the assay 
was 0.5 ^g/m l and samples above 5 ^ig/ml were diluted before re-assay.
c) Antibody Binding Curve
An antibody binding curve was generated for each new batch of labelled albumin or 
antibody, with antibody diluted in assay buffer over a range of titres from 1:320 to 
1:64,000. To 5 assay buffer was added 100^1 diluted label and lOO j^ul diluted 
antibody. The reaction was completed as described above. A typical antibody binding 
curve is shown in Figure 3. The titre of antibody used in subsequent assays was 
chosen to give binding of approximately 60%, commonly 1:32,000.
30
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24500
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ALBUMIN (jug/ml)
Figure 2. Albumin radioimmunoassay: Standard curve
31
% BOUND
100
90
80
70
60
50
40
30
1/10,000 1/20,000 1/30,000 1/40,000 1/50,000 1/60,000
ALBUMIN ANTIBODY TITRE
Figure 3. Albumin radioimmunoassay: Antibody binding curve. The titre 1:32,000 
binds approximately 60% label.
d) Validation
Bovine serum albumin diluted in assay buffer to concentrations 0.1 - 10 ^ g /m l was 
assayed to check for cross-reaction. Figure 4 demonstrates that there is no change in 
the amount of label bound with increasing concentrations of bovine serum albumin, 
over the concentration range 0- 10^ig/ml, showing that there was no cross-reaction of 
bovine albumin with antibody to human albumin. Human albumin, concentration 40 
g/1, was glycated by incubation at 37°C for 1 week in 3 mM NaNj with and without 
100 mmol/1 glucose, then diluted in PbB to concentrations 0.1 - lO ^g/m l before assay. 
Figure 5 shows parallel standard curves, showing that native and glycated albumin 
reacted similarly with the antibody. A urine sample of albumin concentration 21.0 
^g /m l was diluted serially before assay to check for parallelism (Figure 6). Standard 
curves and quality control samples were also assayed in PbB buffer containing glucose
27.8 mmol/1 (5 g/100 ml). Figure 7 demonstrates that standard curves in PbB buffer 
with and without glucose run in parallel, showing that glucose has no effect on the 
binding of antibody.
e) Recoveries
Measured amounts of standard albumin solution were added to urine of known albumin 
concentrations and the solutions assayed to allow determination of recoveries. The 
mean recovery was 96.8% (range 94.0 - 98.2%; Table 2).
f) Quality control
All standard, quality control and unknown samples were assayed in triplicate. Standard
curves were run at the beginning and end of each assay to check for assay drift. Four
quality control samples were prepared from pooled urine samples, aliquoted and
stored at -40°C. The concentration range of the control samples was 2 - 1 5 6 ^ g /m l.
They were assayed on four occasions spread throughout each assay to allow calculation
of intra- and inter-assay coefficients of variation (SD x 100).
mean
For each assay, the mean of each quality control sample and its coefficient of variation 
(CV) was calculated. After the first 10 assays, the overall mean and two standard 
deviations of each control sample were calculated. Subsequent assays were rejected if 
the intra-assay coefficient of variation for any quality control sample was >10%, or if 
any mean value was outwith the reference mean ± 2SD limits or if the non-specific
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Figure 4. Albumin radioimmunosassy: Lack of binding of bovine serum albumin 
(0.1- 10ug/ml) to anti-human albumin immunoglobulin.
Bovine albumin (•)
Human albumin (0
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Figure 5. Albumin radioimmunoassay: Binding of native (o) and glycated albumin
(•) to anti-human albumin immunoglobulin
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Figure 6. Albumin radioimmunoassay: Serial dilution of urine sample (#) containing 
21.0 ug/ml albumin, showing parallelism to standard curve.
36
B, (%)
100
80
60
40
20
4 62 80 10
ALBUMIN (pg/ml)
Figure 7. Albumin radioimmunoassay: Effect of glucose on antigen-antibody 
binding. Albumin standards prepared in buffer with (£$ and without (#)
27.8 mmol/1 glucose.
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Albumin Concentration ^ig/ml) Recovery (%)
Calculated Measured
10.0 9.7 97.0
8.0 7.8 97.5
6.7 6.5 97.0
5.7 5.6 98.2
5.0 4.9 98.0
4.0 3.9 97.5
2.0 1.9 95.0
1.0 0.94 94.0
Table 2 Albumin radioimmunoassay: Recoveries of known amounts of albumin
added to urine.
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binding exceeded 10% or the excess binding was <90%. Charts of the mean albumin 
concentration in each quality control sample in a series of assays are shown in Figures 
8 and 9.
Representative intra- and inter-assay coefficients of variation of the controls are 
shown in Table 3.
g) Comparison with other sensitive albumin assays
The radioimmunoassay was compared with another albumin radioimmunoassay 
performed in the Department of Metabolic Medicine, Guy’s Hospital Medical School, 
London(39). This radioimmunoassay uses rabbit antibody against human albumin 
and polyethylene glycol separation aided by the addition of human immunoglobulins. 
Twenty samples were run in each assay and one communal quality control sample has 
been measured in every assay in each laboratory for 4 years (QC3). The comparison 
of the 2 radioimmunoassays is shown in Figure 10. The correlation coefficient was 
0.96 and the regression equation y = 1.16x+0.18.
Over 4 years, the mean value for the quality control sample in the Newcastle assay was
20.3 jug/ml with a coefficient of variation of 3.9% and 21.0^ag/ml, with CV 4.1% in 
the Guy’s Hospital assay.
The assay was also compared with an immunoturbidimetric assay developed by Dr P 
Bennett, Pheonix, Arizona, USA. Fifty samples were measured blindly in each, assay. 
The correlation coeffecient was 0.99 and regression equation y = 1.02x-0.30 (Figure 
11).
2.2 Microglobulin Assay
1^2-microglobulin was assayed by a modification of the method of Plesner et al(84).
a) Iodination
The iodination was carried out in 0.05M sodium dihydrogen phosphate buffer 
(Na.H2.PO4.H2O), pH 7.5. Human B2“micro8l°bulin (Serotec Limited, Blackthorn, 
Bicester, Oxon, UK), 40^ig in lO^il was added to a vial containing 2 mCi 
Chloramine T, lO^ig in 10 ^ il was added and after mixing gently for 30 s, the reaction 
was terminated by the addition of 1% bovine serum albumin, 300 ul. The reaction
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Figure 8 Albumin radioimmunoassay: Quality control charts; Variation of
samples QCj (upper panel) and QC2 (lower panel).
   ± 2  SD of mean value of the sample in the first 10 assays.
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Figure 9 Albumin radioimmunoassay: Quality control charts; Variation of
samples QC4 (upper panel) and QC3 (lower panel).
—  ± 2 SD of mean value of the sample in the first 10 assays.
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Sample Mean Concentration
(>ig/ml)
Coefficient of Variation 
(%)
Intra-assay Inter-assay
2.3 5.7
4.2 7.0
3.8 4.4
6.5 10.8
QCj
q c 2
QC3
QC4
5.2
1.8
20.4
124.4
Table 3 Albumin radioimmunoassay: Coefficients of variation of the quality
control samples.
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Figure 10 Albumin radioimmunoassay: Comparison of the albumin concentrations 
of 20 samples measured in the Newcastle (y-axis) and Guy’s Hospital (x- 
axis) assays.
line of identity i
 calculated regression line, y=1.16x+0.18
r=0.96
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Figure 11 Albumin radioimmunoassay: Comparison of the albumin concentrations
in 50 samples measured in the Newcastle radioimmunoassay (y-axis) and 
the Phoenix immunoturbidimetric assay (x-axis)
 _______ line of identity
calculated regression line, y=1.02x-0.30
r=0.99
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mixture was applied to a 1 by 50 cm column containing Ultragel AcA 54 (LKB, 
Bromma, Sweden). Elution was by 0.04M sodium dihydrogen phosphate buffer, pH 
8.0, containing 0.2% (w/v) bovine serum albumin (PbB). Approximately 2 ml fractions 
were collected and IO l^iI aliquots counted for 30 s on an NE1600 multi-well gamma 
counter. The B2-microglobulin Peak was pooled and stored at 4°C for use in the 
radioimmunoassay. Specific activity of the labelled protein and the percent bound 
were calculated as for the albumin assay. A typical elution profile is shown in Figure 
12. The peak at fraction 44 is free that at 17 albumin and at 29 ^ 1  B2- 
microglobulin. Fractions 29 and 30 were pooled to form the stock labelled B2- 
microglobulin solution. The specific activity was 47.5/uCi/^ig and the percent 
bound 95.0.
b) fi2 Microglobulin Assay Protocol
B2-m icroglobulin  standards were prepared from  human B2-m icroglobulin  in 
concentrations of 0 - 100^ig/l in assay buffer PbB. Stock labelled B2- microglobulin 
was diluted 10^ il in 6 ml PbB. Rabbit anti-human B2- microglobulin immunoglobulin 
(Dako, Copenhagen, Denmark) was diluted in PbB to a predetermined titre (see binding 
curve). To 100^1 buffer, standard or unknown sample was added 100^ul diluted label 
and 100 u^l diluted antibody. After mixing, the reaction was incubated at 4°C for 18 
hours. Precipitation was by the addition of 500^1 polyethylene glycol 6000, 25% 
(w/w) in assay buffer and 1 0 0 donor calf bovine serum. The tubes were mixed and 
then centrifuged at 2400 rpm at 4°C for 50 min. The supernatant was decanted and 
the precipitate counted on a Packard Auto-Gamma 5780 counter. Total counts in each 
reaction tube were estimated by counting 100^1 diluted label only. Non-specific 
binding was assessed by counting the precipitated radioactivity in a tube containing 100 
jx\ PbB buffer instead of diluted antibody. The binding of label to antibody was 
assessed by inclusion of "excess" reaction tubes containing lOO^ul antibody of titre 1:200 
instead of diluted antibody. Non-specific binding was generally <10% and excess 
binding 90-95%. Serum samples were diluted 1:100 in PbB before assay. A typical 
standard curve is shown in Figure 13. The sensitivity of the assay was 2.5^ig/1.
c) Antibody Binding Curve
An antibody binding curve was performed for each new batch of label or antibody, 
with antibody diluted over a range of titres from 1:200 to 1:50,000. To 100^1 assay 
buffer PbB was added 100 ^il diluted iodinated B2~microglobulin and lOO^il diluted
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Figure 12
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FRACTION NUMBER
20
B2-Microglobulin radioimmunoassay: Iodination.
Separation of ^"M icroglobulin (peak at fraction 29) from 
albumin (peak at fraction 17) and free (peak at fraction 44).
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Figure 13 ^"Microglobulin radioimmunoassay: Standard curve.
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antibody. The reaction was completed as described above. A typical curve is shown in 
Figure 14. The titre antibody used in subsequent assays was chosen to give binding of 
approximately 60%, usually 1:40,000.
d) Validation
Urine and serum samples were diluted serially before assay to check for parallelism. 
Figure 15 shows that serial dilutions of urine and serum samples ran parallel to the 
standard curve.
e) Recoveries
To each of 3 urine and 3 serum samples containing a predetermined concentration of 
132-microglobulin was added a known amount of human l^-m icroglobulin standard 
prior to reassay. Recoveries are shown in Table 4. The mean recovery for urine was 
93.5 (85.1 - 102.9)% and for serum 99.1 (90.0 - 111.5)%.
f) Quality Control
All standard, quality control and unknown samples were assayed in triplicate. Standard 
curves were run at the beginning and end of each assay. Four urine samples, 
concentration range 4.0 - 36.0^pg/1 and three serum samples, range 1.3 - 1.8 mg/1 were 
assayed on four occasions in each assay to check precision. Intra- and inter-assay 
coefficients of variation were calculated (Tables 5 and 6) and the same criteria for 
assay acceptance used as in the albumin assay.
2.3. Urine Samples
Timed overnight urine collections were made into 0.5ml 0.1% thiomersal (Sigma 
Chemical Company, Poole, Dorset, UK) and 0.5 ml 4M NaOH (Sigma Chemical 
Company, Poole, Dorset, UK). Patients were instructed to empty their bladder, 
discarding the urine, immediately before retiring to bed. The time was noted on the 
container. All urine passed during the night was collected. Immediately on rising, the 
bladder was emptied and all the urine collected into the container. The time was again 
noted. From the volume of the sample (ml) and the duration of the collection (min) 
the albumin excretion rate (AER) was calculated:
AER = albumin concentration (ug/mll x volume (ml) ^lg/min 
duration (min)
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Figure 14 ^"Microglobulin radioimmunoassay: Antibody binding curve. A titre of 
1:40,000 binds approximately 60% label.
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Figure 15 ^ “Microglobulin radioimmunoassay: Serial dilution of urine 0  and
serum samples (# ) , both showing parallelism to the l^-m icroglobulin 
standard curve.
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Urine Serum
Concentration £ug/l) Recovery (%) Concentration pug/1) Recovery (%) 
Measured Calculated Measured Calculated
8.0 9.4 85.1 15.5 15.6 99.4
13.5 14.0 96.4 17.6 16.0 90.9
15.4 16.5 93.3 19.0 20.1 94.5
19.6 21.5 91.2 21.9 21.8 100.5
35.0 34.0 102.9 26.2 23.5 111.5
36.0 39.0 92.3 33.0 33.8 97.6
Table 4 l^-Microglobulin radioimmunoassay: Recoveries of l32"micr°S^°t>u^ n *n 
urine and serum
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Sample Mean Concentration 
pJg/1)
Coefficient of Variation 
(%)
Intra-assay Inter-assay
1 6.4 7.2 7.7
2 33.5 4.0 6.1
3 39.5 6.0 3.8
Table 5 B2 -Microglobulin radioimmunoassay: Urine Quality Control Sample
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Sample
1
2
Mean Concentration Coefficient of Variation
(mg/1) (%)
Intra-assay Inter-assay
1.45 2.8 6.0
1.65 6.0 6.0
1.70 5.4 3.4
Table 6 l^-Microglobulin radioimmunoassay: Serum Quality Control Samples
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Aliquots of the first morning urine passed immediately on rising (EMU) were collected 
with no preservative. Aliquots of urine were stored at - 40°C until assay. All samples 
were centrifuged at 2400 rpm at 4°C for 10 min immediately before assay. Every urine 
sample was screened for infection using Nephurtest strips (Boehringer, Mannheim, 
West Germany). Any sample giving a positive leucocyte or n itrite  reaction was 
discarded, to avoid falsely high values due to inflammation of the urinary tract.
2.4. Blood Measurements
Serum for B2-microglobulin measurement was stored at -40°C before assay. Whole 
blood for determination of glycosylated haemoglobin was collected into EDTA before 
assay by the Corning electrophoresis method. The coefficient of variation is 8.0% at a 
glycosylated haemoglobin concentration of 10% and the reference range 5.0-7.5%. 
Plasma and urine creatinine were determined by a modified Jaffe reaction (85) using a 
Beckman A stra autom ated m ulti-channel analyser. Serum fo r fructosam ine 
determination was stored at -40°C before assay by a colourimetric technique using 
n itro b lu e  te trazo lium  ( 86). The re fe ren ce  range was 1.79 - 2.35 mmol 
fructosamine/lOOg albumin.
2.5. Assay of urinary human epidermal growth factor
Human epidermal growth factor (hEGF) was measured in triplicate by a double 
antibody radioimmunoassay(87). hEGF, kindly donated by Dr Gregory, Imperial 
Chemical Industries Ltd, M acclesfield, Cheshire, UK, was iodinated to specific 
activities of 90 - 100 Ci/g by the iodogen method(88). To either 0.1 ml purified 
hEFG standard or urine diluted five-fold was added 0.1 ml specific rabbit anti-hEGF 
serum(89) at a final dilution of 1:24,000 and 0.1 ml ^ I - E G F  (10,000 cpm). The 
antiserum used bound 10 - 15% of total radioactivity added in the absence of 
unlabelled hEGF. After incubation at 4°C for 24 h, the bound and free fractions were 
separated by addition of a second antibody linked to cellulose (Sac-Cel, Wellcome 
Reagents Ltd, Beckenham, Kent, England). The radioactivity of the precipitate was 
counted in a multi-well gamma counter (Gambyt CS-20) and results calculated using a 
standard logistic curve-fit. All samples were assayed in the same batch, the intra-assay 
coefficient of variation being 2.6%. Figure 16 shows a representative dose-response 
curve for purified hEGF standard compared to that given by dilutions of urine in the 
homologous hEGF assay.
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Figure 16 Epidermal growth factor radioimmunoassay: Dose response curves for 
purified hEGF standard (#  ) and dilutions of urine (o ). Each point 
represents the mean of 3 determinations.
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2.6 Ethical Approval
Where appropriate, studies were approved by the Newcastle Area Health Authorities 
Joint Ethical Committee.
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CHAPTER 3
3. Albumin excretion in healthy adults and children
3.1 Aims
The aims of this study were to determine normal ranges for albumin excretion in 
healthy adults and children. Given the difficulties of collecting complete urine samples 
from young children, albumin excretion has also been expressed as albuminrcreatinine 
ratio.
3.2 Methods
Timed overnight urine samples were collected from 106 adults and 64 children. All 
were healthy and taking no medication. The age and sex of each subject were 
recorded. Albumin was measured in all samples for calculation of the albumin 
excretion rate and in children’s samples, creatinine was also estim ated, to allow 
determination of the albuminrcreatinine ratio. Statistical analysis was by Student’s t test 
and Pearson correlation coefficient, as appropriate, in the adult population and by non- 
parametric means in the children.
3.3 Results
(a) Albumin excretion in normal adult subjects
Details of the characteristics of the normal subjects and AER’s are shown in Table 7. 
Males were older than females (p<0.001) and had a significantly higher AER (p<0.005). 
The d istribu tion  of the AER in the population was not norm al (F igure 17). 
Logarithmic transformation to base 10 resulted in a normally distributed population and 
hence logarithmic transformation of AER has been done before statistical analysis in all 
fu rther adult studies. AER results are therefore given as geometric mean x/-j2 
tolerance factors.
There was no correlation of AER with age in the whole group or in either sex.
(b) Albumin excretion in healthy children
After logarithmic transformation, the AER in the 64 normal children was 2.5(0.6-7.0) 
^ug/min (geometric mean x / t 2  tolerance factors), significantly lower than in the adult 
population [5.4(1.7-10.5) ^g/m in; p<0.001]. However, albumin excretion rates and 
albuminrcreatinine ratios were not normally distributed even after logarithmic 
transformation in the children. The results have therefore been analysed using non-
57
parametric tests: the Kendall Rank and Partial Rank correlations and Mann-Whitney 
U test. Details of the children’s results so analysed are given in Table 8. Excretion 
rates were similar in boys and girls but there was a strong correlation of 
AER with age 0*= 0.33, p<0.001; Figure 18). Albumin:creatinine ratios were similar in 
boys and girls, with no correlation with age.
3.4 Discussion
It is difficult to compare the normal ranges established here with others because of 
differences in urine collections and different methods for albumin determination. In 
the only large pub lished  study of a lbum in  ex cre tion  ra te , m easured by 
radioimmunoassay, in a timed overnight urine sample, the geometric mean (95% 
tolerance limits) for AER was 3.2 (1.2-8.6) jig/min (90). In this study, the distribution 
of AER was also positively skewed, but normalised by logarithmic transformation. No 
relationship of AER to age or sex was seen. In other studies on small numbers of 
healthy adults, the AER has been reported as 3.7±2.1 (91), 0.5-10.4(92), 4.5±1.5(37), 
<20(47) and <40 ^ig/min(46). It would thus seem that the normal range found here is 
not unrealistic.
Similarly, the median overnight excretion rate of 2.5 jig/m in in normal children 
com pares well w ith  th a t of D avies(58) bu t not of R ow e(53) who used an 
immunoturbidimetric technique for albumin determination. The latter is known to give 
consistently lower results than values measured by radioimmunoassay(93). Davies also 
found a correlation between age and day and night albumin excretion rates in a large 
group of 374 normal children(58) whereas 2 smaller studies did not(53,56). The 
reasons for these differences are unclear.
The demonstration that albumin excretion rates are significantly lower in children than 
adults, and the relationship of AER to age in children, has important implications for 
studies examining albumin excretion in diabetic children. Age-matched controls will 
obviously be required. The adult discriminant AER values for predicting increased 
risk are not applicable to children.
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All Male Female
Number 106 68 38
Age (years) * 43±18 47±19** 36±13
(17-80) (17-80) (22-69)
AER (jig/min)^ 5.4 5.9 4.4
(1.7-10.5) (2.0-11.2)* (1.4-9.3)
* mean±2SD (range)
^ geometric mean (x/i-2 tolerance factors)
*, **: p<0.005, p<0.001, males versus females
Table 7 Albumin excretion rates (AER) in the normal adult population.
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Figure 17 Distribution of albumin excretion rates (AER) in the norm al adult 
population.
All Male Female
Number 64 32 32
Age1 9.0 8.0 9.9
(years) (3-17) (3-17) (4-15)
AER2 2.4 2.2 2.4
^lg/min) (0.2- 20.8) (0.2-20.8) (0.2- 10.6)
Albumin: 0.95 0.84 0.96
creatinine ratio2 (0.40-3.7) (0.4-5.85) (0.43-7.21)
^ig/mmol)
1 mean (range)
2 median (range)
Table 8 Albumin excretion in healthy children.
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Figure 18 Albumin excretion in healthy children: Effect of age 
y  = 0.33
p<0.001
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CHAPTER 4
Comparison of the prevalence and associated features of abnormal albumin excretion in 
insulin-dependent and non-insulin dependent diabetes
4.1 Aims
The aims of this study were to establish the prevalence of the various degrees of 
abnormal albumin excretion in an unselected diabetic out-patient population and to 
compare insulin-dependent and non-insulin dependent diabetic patients. The 
relationship of albumin excretion to age, sex, duration of diabetes, blood pressure, 
glycaemic control and the presence of the other complications of diabetes is examined.
4.2 Subjects and Method
Diabetic patients
All adult diabetic patients attending 3 hospital diabetic clinics over a 6 month period 
were asked to provide a timed overnight urine sample. Written instructions and 
containers were distributed at one clinic visit and the patients asked to collect the 
sample on the night before their next clinic visit. The prevalence of the various 
degrees of album inuria in the clinic population was determined. Patients were 
classified as insulin-dependent if they had commenced on insulin therapy within one 
month of diagnosis and remained on it continuously since. Those not fulfilling these 
criteria were classified as non-insulin dependent. Four patients with secondary 
diabetes were excluded. No patients was studied within 6 months of diagnosis of 
diabetes or within 1 month of acute metabolic decompensation.
Clinical data
For each diabetic patient who provided a timed overnight urine sample as above,
information about the age, sex, known duration and treatment of diabetes (diet alone,
diet plus oral hypoglycaemic agents, diet plus insulin) was obtained from the medical
records. Non-insulin dependent patients were subdivided into three groups on the
basis of treatment with diet alone, oral hypoglycaemic agents or insulin. Treatment of
hypertension and anv other, medical condition was noted, as was the presence or
Retinopathy was assessed by fundoscopy through dilated pupils, 
absence of the other complications ot diaoetes. J^Ketinopatny was aennea as any noted
abnormality typical of diabetes; peripheral vascular disease as symptomatic intermittent
claudication or absent dorsalis pedis and posterior tibial pulses or a past or present
history of gangrene or amputation; peripheral neuropathy as symptoms of paraesthesiae
or typical stocking sensory deficit and absent ankle jerks; ischaemic heart disease as a
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typical history of angina pectoris or a previous myocardial infarction as judged by 
history, electro-cardiographic and enzymatic changes. A history of non-diabetic renal 
disease was also noted. Blood pressure was measured on the day of the clinic visit 
(sitting, after 5 min rest, to the nearest 2mm Hg, diastolic phase V, using a standard cuff) 
anc  ^blood drawn for glycosylated haemoglobin estimation. __ ____________
Statistical methods
All statistical analysis was carried out using the Statistical Package for the Social 
Services (94). Albumin excretion rates in the normal and diabetic populations were 
positively skewed, hence the rates have been logarithmically transform ed before 
analysis. Differences between groups were assessed by Student’s t test or)(3 test as 
appropria te . Individual correlations were assessed by the Pearson correlation  
coefficient and multiple relationships by multivariate analysis using step-wise entry, 
with log AER as the dependent variable.
4.3 Results
Prevalence of the various degrees of albuminuria
Of the 1456 subjects approached, 1031 (71%) provided a timed overnight urine sample. 
Seventy nine (75 women and 4 men) gave a positive Nephur test for blood, leucocytes 
or nitrites and were excluded. Twelve men had a history of other renal tract disease 
(six malignancies, three calculi, one glomerulonephritis, one renal tuberculosis, one 
congenital abnormality) and were also excluded, leaving 940 for analysis. Five hundred 
and twenty four were defined as NIDDM and 416 as IDDM. Of the 940 patients, 671 
(71.4%) had AER within the normal range (<10.5 ^lg/min), 138 (14.7%) had AER 
between 10.6 and 29.9/pg/min, (elevated excretion but not known to be at risk), 79 
(8.4%) had AER 30-150 ^g/m in (at risk microalbuminuria) and 52 (5.5%) AER >150 
^pg/min (approaching clinical nephropathy). The corresponding figures for IDDM and 
NIDDM are given in Table 9. The mean log AER was higher in the NIDDM group 
(t=2.62, p<0.009) and the proportion of NIDDM patients with abnormal rates of 
albumin excretion was higher than in IDDM fc?=15.2, p<0.002).
Association of albuminuria with other clinical features
Because of the difference in albumin excretion, patients with insulin-dependent and 
non-insulin dependent diabetes have been analysed separately. Details of the patient 
characteristics are given in Table 10. As might be expected, non-insulin dependent 
diabetic patients were older at the time of study than insulin-dependent patients, older
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AER £ug/min)
<<10.5 10.6-29.9 30-150 >150
All patients 671 (71.4) 138 (14.7) 79 (8.4) 52 (5.5)
IDDM 323 (77.7) 45 (10.8) 28 (6.7) 20 (4.8)
NIDDM 348 (66.4) 93 (17.8) 51 (9.7) 32 (6.1)
Number (%)
Table 9 Distribution of the various levels of albumin excretion rate (AER) in the 
total diabetic population and IDDM and NIDDM patients.
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IDDM NIDDM
215:201Sex M:F
Age (years) 45±16
(14-87)
Duration of diabetes (years) 18±12
(1-55)
Age at diagnosis (years) 27±14
(1-71)
Glycosylated haemoglobin (%) 10.0±2.1
(5.5-19.0)
Systolic BP (mmHg) 135±23
Diastolic BP (mmHg) 77±10
Mean ± SD (range)
*** p<0.001 IDDM versus NIDDM
272:252
65±10***
(19-86)
8±7***
(1-33)
57+11***
(19-85)
10.1±2.7
(4.9-18.9)
151±25***
83±11***
Table 10 Characteristics of insulin-dependent and non-insulin dependent diabetic 
patients.
at diagnosis and had a shorter duration of diabetes. The prevalence of other long-term 
com plications of diabetes and of treated  hypertension is given in Table 11. 
Retinopathy was commoner in IDDM but peripheral vascular disease, ischaemic heart
disease and treated hypertension were more frequent in NIDDM.
Because of small numbers, all patients with retinopathy, whether background or proliferative, have been
analysed together, j  Perf° rmed on data from all patients, ____
Univariate analysisj^hdwed that~In IDDM, AER was related to known duration of
diabetes (r=0.21, p<0.001), systolic blood pressure (r=0.18, p<0.001), male sex (t=2.46,
p<0.002), and the presence of retinopathy (t=4.61, p<0.001), peripheral vascular disease
(t=2.85, p<0.01) and peripheral neuropathy (t=2.50, p<0.02). In NIDDM, AER
correlated with known duration of diabetes, (r=0.18, p<0.001), systolic (r=0.20, p<0.001)
and diastolic blood pressure (r=0.17, p<0.001) and to the presence of peripheral
vascular disease (t=4.12, p<0.001), retinopathy (t=3.66, pcO.OOl) and ischaemic heart
disease (t=2.64, p<0.002). Tables 12 and 13 demonstrate the effect of the various
variables on the four categories of albuminuria. In IDDM, duration of diabetes was
significantly increased in the three categories of abnormal excretion compared with the
normoalbuminuric patients. Systolic blood pressure increased as AER increased, but
reached significance only in the group with AER >150 ^ g /m in . The prevalence of
retinopathy was more than doubled in those with AER >150^ug/min compared with the
normoalbuminuric patients. In NIDDM, those patients with elevated AER had a longer
duration of diabetes. Systolic blood pressure was significantly increased in all
abnormal groups compared with the normoalbuminuric group, whereas diastolic BP was
increased only in the range of AER 30-150^g/min. Retinopathy, peripheral vascular
disease and ischaemic heart disease were commoner in those patients with abnormal
albumin excretion.
Multiple regression analysis, using log AER as the dependent variable and with all 
factors individually correlating with log AER entered in step-wise fashion, revealed 
that in IDDM, only male sex and presence of retinopathy remained significant (r=0.28, 
p<0.001). A regression equation was formulated:
logAER = 0.705 + (0.243 x logAER if retinopathy)
+ (0.146 x logAER if male)
Thus the ratio of AER with and without retinopathy is 1.75 and male to female is 1.40.
Figure 19 illustrates the effect of sex and Figure 20 of retinopathy in AER in IDDM.
At all levels of album in excretion, AER is higher in males and in those w ith 
retinopathy.
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IDDM 
n (%)
NIDDM 
n (%)
Retinopathy
Peripheral vascular disease
Ischaemic heart disease
Peripheral neuropathy
Treated hypertension
*** p< 0.001
125 (30.1) 96 (18.3)***
28 (6.8) 78 (14.9)***
34 (8.2) 122 (23.4)***
31(7.5) 59(11.3)
21 (5.0) 94 (18.0)***
Table 11 Presence of other complications and of treated hypertension in the two 
groups of diabetic patients.
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Factor AER ^Lig/min)
<<10.5 10.6-29.9 30-150 >150
Duration
(years)
17± 11 22±12** 22±12* 25±12***
Systolic BP 
(mmHg)
133±22 137±23 140±23 150±22**
Male sex (%) 51 52 69 45
Retinopathy (%) 27 41* * 41
Mean ± SD
*, **, *** p<0.05, p<0.02, p<0.005 versus normoalbuminuric patients
Table 12 Effect of duration of diabetes, systolic blood pressure, male sex and the 
presence of retinopathy on the 4 ranges of albumin excretion in IDDM.
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Factor
^10.5
AER (^ig/min) 
10.6-29.9 30-150 >150
Duration
(years)
7±7 9±8* 10±9* 10±7*
Systolic BP 
(mmHg)
147±24 157±27*** 157±25** 162126***
Diastolic BP 
(mmHg)
82±11 84±12 89±11*** 85±10
Retinopathy (%) 15 22 3 5 * * * 38**
PVD (%) 10 21 31* * *
Ischaemic heart 19 
disease (%)
29* 38*** 35
Mean ± SD
*, **, *** p<0.05, p<0.02, p<0.005 versus normoalbuminuric patients 
PVD: Peripheral vascular disease
Table 13 Effect of duration of diabetes, systolic and diastolic blood pressure and 
other complications on the four ranges of albumin excretion in NIDDM.
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Figure 19 The influence of sex on albumin excretion rate (AER) in IDDM.
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For NIDDM, multiple regression analysis showed a significant relationship of log AER 
to systolic blood pressure, peripheral vascular disease and retinopathy (r=0.31, pcO.OOl), 
such that:
logAER = 0.249 + (0.004 per mm SBP)
+ (0.266 x logAER if PVD)
+ (0.179 x logAER if retinopthy)
Thus for each mm Hg systolic blood pressure, AER increases by a factor of 1.01 and 
the ratio of AER with and without retinopathy is 1.51 and with and without peripheral 
vascular disease is 1.85. Figures 21 and 22 show the effect of retinopathy and 
peripheral vascular disease on AER in NIDDM and Figure 23 the effect of systolic 
blood pressure. Again, the effect of all three variables is seen at all levels of AER.
At-risk microalbuminuria (AER 30-150 ^ig/min) was observed at all durations of
diabetes in NIDDM patients. By contrast, in IDDM only one patient with duration of 
diabetes less than 5 years and only four with duration greater than 30 years had at-risk 
microalbuminuria.
4.4 Discussion
It appears from these results that, in this clinic population, abnormal albumin excretion 
is common, 28.6% of all patients having an AER outwith the normal range. Although 
AER was higher in normal adult males compared to females (chapter 3), no allowance 
for sex has been made in any of the papers examining the levels of AER predictive of 
end-stage diabetic nephropathy(19,37,45,46,47,48). For this reason one combined 
normal range has been used for the current population, regardless of sex.
Comparison of the prevalence of abnormal AER shown here with other papers is 
difficult, because of differences in populations studied, in the type of urine collections 
and methods used for measuring albumin. In one large study of an unselected diabetic 
out-patient clinic population in Denmark, using albumin concentrations in an early 
morning urine sample, 23% had albumin concentrations >30 mg/1, with 11.9% 
exhibiting concentrations >30 mg/1 but being Albustix negative (95). No distinction 
was made between IDDM and NIDDM, although albumin concentrations >30 mg/1 were 
less common in those patients whose diabetes was diagnosed after the age of 50 years. 
In another recently published Danish study of 957 IDDM patients, 22% had AER 20- 
200^ig/min in a 24h collection and 19% AER >200^ig/min (96). A British community
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based study has recently reported a prevalence of at-risk microalbuminuria (AER >30 
^ug/min in a timed overnight sample) of 7% in 450 patients and a prevalence of 5.1% of 
Albustix positive proteinuria(97).
Two British studies have demonstrated a prevalence of persistent Albustix positive 
proteinuria of 9.4% in insulin-treated patients(51), and 2.7% in all patients(50), whilst 
an American group found a prevalence of 8.2% at diagnosis of diabetes, rising to 
24.6% after 20 years(98). These results suggest that both m icroalbum inuria and 
persistent proteinuria may be commoner in Denmark and the USA than in Britain. 
W hether the d ifferences are real, or simply a reflec tion  of population bias or 
differences in albumin analysis, remains to be seen. Real differences might perhaps 
indicate different genetic susceptibilities to diabetic nephropathy or environmental 
influences such as diet.
In our clinic population, abnormal albumin excretion is commoner in NIDDM than in 
IDDM, one-third of patients with non-insulin dependent diabetes having abnormal 
albumin excretion compared with 22 per cent in IDDM. Both mean systolic and 
diastolic blood pressure were higher in the NIDDM group than the IDDM group and 
more NIDDM patients were taking anti-hypertensive agents. Systolic blood pressure 
was significantly related to AER in NIDDM. Thus it may be that the increased 
prevalence of abnormal AER in NIDDM is related to higher blood pressure, producing 
increased albumin excretion but without specific diabetic renal disease. Non-diabetic 
renal disease is thought to be commoner in NIDDM than in IDDM (99) and 
hypertension per se is known to increase albumin excretion(lOO).
Although NIDDM patients were older than IDDM patients, no effect of age on AER 
was observed in either diabetic group or in the normal subjects. It therefore seems 
unlikely that the higher AER in the NIDDM patients was due to increasing age. Blood 
glucose control, as measured by glycosylated haemoglobin, was similar in the two 
groups of patients and had no influence on AER and so is also unlikely to account for 
the difference between AER in IDDM and NIDDM. A recently published study, by 
contrast, found no influence of type of diabetes on AER but found positive 
associations with blood glucose, sex, systolic blood pressure and smoking but not with 
retinopathy(lOl). These differences are perhaps explained by the fact that in this
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study, patients with Albustix positive proteinuria were excluded from analysis and 
AER was corrected for body surface area.
At-risk microalbuminuria (AER 30-150 ^g/m in) occurred in NIDDM at all durations 
of diabetes, whereas in IDDM only one patient with duration <5 years had such an 
excretion rate. It is well recognised that, in NIDDM, specific diabetic complications, 
particularly retinopathy may be present at diagnosis of diabetes, presumably because of 
the long silent phase of NIDDM. Our data suggest that abnormal albumin excretion, a 
m arker of early renal damage, may also be detectable shortly after diagnosis of 
NIDDM. Since no patient was studied within 6 months of diagnosis, this is unlikely to 
be the transiently increased albumin excretion seen with severely uncontrolled 
diabetes(42,43,102,103,104), but perhaps reflects the fact that many of these patients 
may have had diabetes for a considerable time before diagnosis, and that significant, 
permanent renal damage occurred during this period.
The presence of retinopathy strongly influenced AER in both IDDM and NIDDM, 
whereas male sex was significantly related only in IDDM and systolic blood pressure 
and peripheral vascular disease in NIDDM. The association of retinopathy and 
A lbustix -positive  p ro te inuria  has long been recognised(7 ,20) and it has been 
demonstrated that those IDDM patients with AER >15 ug/min are more likely to 
progress to proliferative retinopathy as well as to persistent proteinuria(37). Our 
findings suggest that NIDDM patients with abnormal albumin excretion are also at risk 
of retinopathy. The close link of retinopathy to albumin excretion in both IDDM and 
NIDDM suggests a common aetiological mechanism dependent on the diabetic state. In 
NIDDM, AER in the range 30-150 ^g /m in  is predictive of early death(48) from 
cardiovascular disease(19). Thus it is not surprising that AER is closely related to 
systolic blood pressure and the presence of peripheral vascular disease in NIDDM. 
Abnormal albumin excretion in NIDDM may perhaps be due to reno-vascular disease 
rather than to specific diabetic renal disease.
Although the associations with AER shown here are statistically significant, the 
correlation coefficients are small and account for only a small proportion of the 
variability in AER. One possible explanation is the large day-to-day variation in 
AER, some individuals having a coefficient of variation in AER of 40 per cent(105). 
This was a cross-sectional study and thus may not truly represent preceding events in
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the development of diabetic complications. Other factors, not identified here, such as 
genetics, blood lipids or cigarette smoking, may also influence AER.
In summary, an increased incidence of abnormal albumin excretion in NIDDM 
compared with IDDM has been shown. A t-risk microalbuminuria occurred shortly 
after diagnosis in NIDDM but was rare in IDDM until after 5 years of diabetes. The 
features significantly influencing AER were d ifferen t in NIDDM and IDDM, 
retinopathy being strongly associated in both groups but male sex only in IDDM and 
systolic blood pressure and peripheral vascular disease in NIDDM. This is perhaps a 
reflection of the different risks imposed by microalbuminuria on the 2 groups, IDDM 
patients being at increased risk of end-stage renal disease whilst NIDDM patients are at 
risk of early mortality from cardiovascular causes.
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CHAPTER 5
Albumin excretion in children with insulin-dependent diabetes
5.1 Aims
The overnight albumin excretion rates in a group of children with IDDM have been 
compared with AER in normal children and healthy adults. In both groups of children 
albumin:creatinine ratios have also been measured. The relationship of AER to age and 
sex in the diabetic children has been explored.
5.2 Subjects and methods
Eighty two diabetic children were requested by post to collect a timed overnight urine 
sample in connection with their annual "birthday check". A container and written 
instructions were posted to the parents, asking for the sample to be collected on the 
night prior to the clinic visit. The age, sex, duration of diabetes and any drug 
treatment were noted. The presence or absence of retinopathy and the blood pressure 
(sitting, diastolic phase V) were recorded by one of two observers. Blood was drawn 
on the same day for determination of glycosylated haemoglobin.
Urinary albumin and creatinine were measured and results expressed as AER ^ug/min) 
and albuminrcreatinine ratio (mg/mmol). The results in the diabetic children were 
compared with those in healthy children and adults described in Chapter 3.
Statistical methods
Albumin excretion rates and albumin:creatinine ratios were positively skewed even 
after logarithmic transformation in the two groups of children. Results have therefore 
been analysed by non-parametric tests, using the Kendall Rank and Partial Rank 
correlation coefficients and Mann Whitney U test.
5.3 Results
Of the 82 children approached, 68 provided a timed overnight urine sample, giving a 
response rate of 83%: 41 boys and 27 girls were studied. Apart from 1 boy who had 
had bilateral cataract extractions, none had evidence of the long-term complications of 
diabetes. All were Albustix negative on routine clinic testing of the urine. The mean 
duration of diabetes was 3.8 years (range 1-13) and HbAj 9.9% (5.6-14.3). Mean AER 
was similar to that of the non-diabetic children and the groups were well matched for 
age and sex (Table 14). AER correlated with age Q^0.36, p<0.001; Figure 24), as it
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Normal Children Diabetic Children
All Male Female All Male Female
Number 64 32 32 68 41 27
Age 9.0 8.0 9.9 10.3 9.3 11.9**
(years) (3-17) (3-17) (4-15) (3-17) (4-15) (3-17)
HbAj - 9.9 9.7 10.1
(%) (5.6-14.3) (5.6-13.7) (5.7-14.3)
Duration of - - - 3.8 3.7 4.1
diabetes
(years) (1-13) (1-13) (1-10)
Mean (range)
**p<0.005 diabetic girls v boys
Table 14 Characteristics of the normal and diabetic children studied
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Figure 24 Albumin excretion in diabetic children: effect of age 
7* =0.36, p<0.001
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did in the non-diabetic children, and also weakly with duration of diabetes (>-=0.22, 
p<0.01), but when controlled for age this became insignificant. There was no 
correlation of AER with H bA j. AER was significantly lower in both groups of 
children than in the adult population (p<0.001; Table 15).
Albumin excretion rates in diabetic girls were higher than in boys [3.6(0.9-9.5) versus 
2.1(0.7-8.2)^ig/min; p=0.02; Table 15]. However, the girls were significantly older 
than the boys [11.9(3-17) versus 9.3(4-15) years; p=0.005]. It was possible to match 23 
female diabetic children (85%) with boys to within 2 years for age and duration of 
diabetes, so that there was no difference between the mean age [10.9(4-17) versus 
11.1(4-15) years] or duration [3.7(1-10) versus 3.7(1-12) years] of the groups. There 
was no significant difference in AER between these groups [3.1(0.9-9.5) versus 2.4(1.1- 
7.5) ^ g /m in: t=1.49, p>0.1] suggesting that the higher excretion rate observed in the 
total population of diabetic girls was due to the greater age.
Albumin:creatinine ratios were similar to the non-diabetic children [1.00(0.43-2.58) 
versus 0.95(0.40-3.7) mg/mmol] and did not correlate with age, HbAj or duration of 
diabetes.
5.4 Discussion
The results demonstrate that albumin excretion rates are significantly lower in children 
than adults and that the excretion rate increases with age in both normal and diabetic 
children. Two previous studies(53,56) have failed to demonstrate any effect of age on 
normal children but in a large study of 374 normal children(58) both day and night 
albumin excretion rates correlated strongly with age. Similarly, in diabetic children, 
the published data is unclear. Davies(54) and Rowe(53) demonstrated a relationship 
with age but Ellis(56) and Brochner-Mortensen(57) failed to find it. None of our 
diabetic children had albumin excretion rates in the adult microalbuminuric range.
Direct comparison of albumin excretion rates between studies is difficult because of 
differences in sample collection and in albumin assay techniques. We have chosen to 
collect timed overnight urine samples in an attempt to minimise the effect of the 
exaggerated albumin excretion response to exercise observed in childhood(59,106,107), 
and adult diabetes(60,82). Two studies have found an increased overnight excretion 
rate in diabetic over normal children(53,54) which we did not. Our children however
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AER pjg/min)
n median range
Adults 106 4.3 1.6-17.6
Non-diabetic children
Total 64 2.4 0.2-20.8
Boys 32 2.2 0.2-20.8
Girls 32 2.4 0.2-10.6
Diabetic children
Total 68 2.5 0.7-9.5
Boys 41 2.1 0.7-8.2
Girls 27 3.6* 0.9-9.5
* p=0.02 diabetic girls v boys
Table 15 Albumin excretion rates in diabetic and non-diabetic children and normal 
adults
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were younger and had diabetes of shorter duration. These studies also demonstrated a 
significant relationship between AER and duration of diabetes.
The literature examining the correlation of albumin excretion rate with metabolic 
control is confusing. We have shown no correlation of HbAj with albumin excretion 
rate, a finding observed previously(55,56). However, Davies demonstrated significant 
relationships of AER with H bAj, mean blood glucose and M values(54) and Rowe 
with HbAj(53). It has also been demonstrated that the exaggerated albumin excretion 
in response to exercise in diabetic children can be decreased by improving metabolic 
control(106). M icroalbuminuria in adults can be reduced by the institu tion of 
normoglycaemia in 24 hours(102). Since the half-life of HbAj is approximately 6 
weeks, a close correlation between AER and HbAj might not be expected.
In conclusion, AER is significantly lower in normal and diabetic children than in 
adults and correlates with age in all children. It is therefore unlikely that the cut-off 
points suitable for defining microalbuminuria in adults can be applied to children. A 
long-term  fo llow -up study is needed to determ ine the natural h isto ry  of the 
development of microalbuminuria in children and the cu t-off limits predictive of 
future diabetic nephropathy.
Since this study was completed, a further paper has shown a prevalence of 37% of 
microalbuminuria in insulin-dependent diabetic children aged over 15 years(108). No 
children under the age of 15 had microalbuminuria.
The absence of children with abnormal albumin excretion, so that all the excretion rates were within the \ 
-j rather narrow normal range may also have contributed to the lack of correlation between AER and HbAj ; 
demonstrated here.
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CHAPTER 6
Dav-to-dav and longer term variation in albumin excretion
6.1 Aims
This study was undertaken to evaluate the day-to-day variation of albumin excretion 
in normal subjects and diabetic patients with varying degrees of albuminuria and to 
observe the rate of change of album in excretion in norm oalbum inuric and 
microalbuminuric diabetic subjects over a longer time.
6.2 Subjects and Methods
(a) Dav-to-dav variation
Eight normal subjects and 21 patients with IDDM collected a minimum of 5 timed 
overnight urine samples in 6 weeks. The diabetic patients were characterised on the 
basis of their mean AER:
Group 1 : AER^10.5^ig/min 
Group 2 : AER 10.6-150^ig/min 
Group 3 : AER >150^ig/min
Characteristics of the subjects are given in Table 16. No subject took any medication 
other than insulin during the study and all remained healthy over the 6 weeks. 
Coefficients of variation of AER were calculated for each patient.
(b) Long-term follow-up
Ten insulin-dependent diabetic patients with normal AER collected one timed 
overnight urine sample every 6 weeks for 60 weeks. Eight IDDM patients with 
normoalbuminuria and 9 with AER 10.6-150 ^ ig/min collected a minimum of one urine 
sample every 6 months for at least 18 months.
6.3 Results
(a) Dav-to-dav variation
Table 16 gives the characteristics of the subjects studied and the mean coefficients of 
variation for the normal and the 3 diabetic groups. The mean CV in each group is 
high, and there is a wide fluctuation in the variation, as seen by the large range of the 
CV’s. However, all normal subjects remained w ithin the normal range. In the 
normoalbuminuric diabetic group (group 1), 2 subjects on 1 occasion and 1 subject on
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Normal subjects Diabetic subjects
Group 1 Group 2 Group 3
Number 8 9 6 6
Age (years) 30.9 34.7 47.2 33.0
(26-34) (23-46) (37-54) (21-46)
Sex (M:F) 5:3 5:4 5:1 5:1
Number of 9.4 5.9 6 6
urine collections (7-11) (5-6) (6) (6)
(range)
CV of AER (%) 13.1 47.2 17.0 10.5
(8.3-16.9) (10.8-73.3) (4.7-52.9) (5.7-16.1)
Initial AER 4.1 3.3 34.2 366
(^g/min) (3.0-5.6) (2.3-6.9) (16.6-116.1) (221-1558)
Mean (range)
AER: albumin excretion rate 
CV: coefficient of variation
Table 16 Day-to-day variation in albumin excretion in normal and diabetic 
subjects.
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2 occasions had AER >10.5 ^ g /m in . In group 2, 1 subject on 1 occasion had AER 
<10.5^ag/min. In the macroalbuminuric group (group 3) 1 subject on 1 occasion and 2 
subjects on 2 occasions had AER <150^ig/min.
(b) Longer term follow-up
Figure 25 illustrates the change in AER measured every 6 weeks for 60 weeks in a 
group of 10 IDDM patients initially with normal AER. The mean change in AER over 
the 60 weeks was +44.6 (-58.6 - +125.0)% of the initial value [mean(range)]. One 
subject showed fluctuations in AER outwith the normal range, AER increasing from
8.1 to 17.4 ^jig/min during the 60 weeks. In the other 9 patients, AER was always 
<10.5^g/min.
Follow-up for a longer period of time (18 to 30 months) revealed rates of changes in 
AER [mean % change(range)] of +11.3(—31.4 - +105.5)% per year in normoalbuminuric 
and +1.3 (-44.4 - +101.8)% per year in microalbuminuric patients. Figure 26 illustrates 
the results for all patients and Figure 27 representative individual changes. One 
normoalbuminuric patient became microalbuminuric (AER from 7.9 - 18.9^ug/min in 
30 months), one microalbuminuric became normoalbuminuric (initial AER 40.1 
^pg/m in, 3 out of 4 subsequent measurem ents <10.5 ^pg/m in) and 2 became 
macroproteinuric (initial AER’s 132 and 80^ig/min).
6.4 Discussion
The high day-to-day variability in AER in both normal subjects and diabetic patients 
with all degrees of albuminuria has major implications for studies investigating the 
effect of various therapeutic manoeuvres on albumin excretion. M ultiple urine 
collections are necessary to ensure that any change in AER observed is due to a "true" 
change and not simply natural variation. There are many known causes for varying 
albumin excretion, including posture(42,54,58), exercise(59,60), hydration and dietary 
protein intake(61). In addition, in the diabetic person, acute changes in blood glucose 
concentrations may be reflected by changes in AER(42,43,102).
The risk to those diabetic patients fluctuating from normal to abnormal AER is 
unknown. It has long been appreciated that persistent Albustix positive proteinuria is 
preceded by a stage of intermittent proteinuria. It is possible that a similar stage of 
"intermittent microalbuminuria" exists before the higher AER levels become persistent.
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(jjg/min)
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Figure 25 Long-term changes in albumin excretion rates (AER) in 10 IDDM 
patients with initially normal albumin excretion
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Long-term changes in albumin excretion rates (AER) in 8 
normoalbuminuric and 9 microalbuminuric IDDM patients.
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Figure 27 Changes in albumin excretion rate (AER) in 6 IDDM patients. 
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Obviously, multiple testing is required before an individual is assigned to a particular 
stage of diabetic nephropathy. However, it is noteworthy that several of the studies 
showing that microalbuminuria is predictive of clinical nephropathy were based on 
single urine collections(45,46,47,48).
Little inform ation is available on the rate of change of albumin excretion in the 
progression either from normoalbuminuria to microalbuminuria or microalbuminuria to 
clinical proteinuria. The data presented here suggests that the mean rate of change is 
rather slow, although there is a wide variation between individuals. In the studies 
showing that microalbuminuria predicts the later development of clinical proteinuria, 
the shortest fo llow -up time was 6 years(46,47) and the longest 14(45). In a 
longitudinal study of 10 IDDM patients with elevated albumin excretion followed for a 
mean of 4.9 years, the mean increase in AER was 19.8% per year, but with a range of 
-7.3 to 58.5% per year(109). Such a wide variation in rate of progression mimics that 
seen in persistent proteinuria, where although the rate of decline in renal function is 
constan t fo r any in d iv id u a l p a tie n t, large v a ria tio n s  ex ist betw een 
patients(9,20,21,110). In any trial of therapeutic intervention, the effect of this large 
variability must be allowed for.
A recently published small study observing albumin excretion in both IDDM and 
NIDDM patients over a mean of 7 years, confirmed that transient episodes of micro- 
and macroalbuminuria often occur before m icro- or macroalbum inuria become 
persistent(lll). In this study, the transition time from microalbuminuria to persistent 
proteinuria varied from 3 to 5 years, a considerably shorter time than has previously 
been thought.
It is thus im perative that large natural h istory studies are com pleted and that 
intervention studies have sufficient power to allow for wide intra- and inter individual 
variation in changes in albumin excretion.
In the study described here, and in the previously reported papers, the numbers of patients studied and the 
observations made were rather small. This may account, at least in part, for the large variations in rate of 
change of AER.
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CHAPTER 7
The effect of Bromhexine on albumin excretion in insulin-dependent diabetes
7.1 Aims
The aim of this study was to examine the effect of the mucolytic agent bromhexine on 
albumin excretion in the various stages of albuminuria in IDDM.
7.2 Subjects and methods
Subjects
Twenty one IDDM patients were studied. They were divided into 3 groups on the 
basis of overnight albumin excretion rates in at least 2 out of 3 sterile, ketone-free 
urine collections:
Group 1 : normoalbuminuric, AER^lO.S^g/min; n=9 
Group 2 : microalbuminuric, AER 10.6-150^ug/min; n=6 
Group 3 : macroalbuminuric, AER >150^ig/min; n=6
Patient characteristics are shown in Tables 17 and 18. Those in group 2 were older 
than in group 1 [47(37-54) versus 35(23-46) years; mean (range); p<0.01] and group 3 
[33(21-46) years; p<0.01]. Systolic blood pressure was higher in groups 2 and 3 
compared to group 1 [137(118-142) and 141(132-146) versus 122(112-142) mmHg; 
p<0.01 and p<0.001]. Diastolic blood pressure was higher in group 3 compared with 
group 1 [87(80-94) versus 79(72-90) mmHg; p<0.05]. One patient in group 3 took 
carbamazepine for painful peripheral neuropathy and thyroxine for auto-immune 
thyroid disease, in constant dosage throughout the study. No other subject took any 
medication other than insulin during the study and diet was unaltered.
Study design ! cr0ss-over
The study was a placebo-controlled, double-blind^randomised trial. Subjects were 
randomised at baseline, within their albumin excretion groups, to receive bromhexine 8 
mg or placebo tablets, three tablets three times a day, each for 4 weeks. There was a 2 
week "wash-out" period between each treatment period when all patients took placebo 
tablets. Clinical and laboratory measurements were made at the beginning and end of 
each treatm ent period. Patients collected 3 timed overnight urine samples for 
measurement of albumin and 132-micr°gl°t>ulin at each time point. Blood was drawn 
for determ ination of H bA j, serum l^-m icroglobulin , fructosam ine, and plasma 
creatinine. Blood pressure was measured in the sitting position after 5 minutes rest,
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Group
1 2
Age 35 47**
(years) (23-46) (37-54)
Duration diabetes 16 23
(years) (6-29) (7-32)
Retinopathy 3:0 4:2
(Background : Proliferative)
HbAj 8.1 10.6*
(%) (6.6-10.7) (8.1-13.1)
Fructosamine 3.05 3.09
(mmol/lOOg albumin) (2.55-3.78) (2.63-3.55)
Systolic Blood Pressure 122 137**
(mmHg) (112-142) (118-142)
Diastolic Blood Pressure 79 81
(mmHg) (72-90) (80-84)
Mean (range)
*, **, *** p<0.05, p<0.01, p<0.001 versus group 1 
++ p<0.01 group 3 versus group 2
Table 17 Effect of bromhexine on albumin excretion in IDDM: 
Patient characteristics at baseline.
3
33++
(21-46)
24
(19-31)
3:3
10.2*
(8.6-11.7)
3 23
(2.79-3.56)
141***
(132-146)
87*
(80-94)
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1GROUP
2 3
AER 3.2 36*** 3 2 1 * ^
pug/min) (2.1-8.8) (22-96) (202-1216)
J32"M excretion rate 28 68 33
(ng/min) (7-85) (4-541) (14-210)
Serum l^ -M  1.4 1.8 1.8
(mg/1) (1.2-1.9) (1.5-2.0) 1.5-2.0)
Serum creatinine 89 87 97
pimol/1) (59-118) (68-118) (82-124)
B2-M : B2~ Microglobulin
*** p<0.001 versus group 1 
+++ pcO.OOl versus group 2
Table 18 Effect of bromhexine on albumin excretion in IDDM: 
Renal characteristics at baseline
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using Korotkoff phase V diastolic pressure. A tablet count was performed to check 
compliance. On the day prior to each clinic visit, patients performed 4 capillary blood 
glucose tests using BM Test Glycemie 1-44 strips (Boehringer, Mannheim, West 
Germany), one test before each main meal and one before bed. The test strips were 
returned to an air-tight container and brought to hospital next day, where they were 
read by reflectance meter.
Statistical analysis
Results were analysed at the end of each treatment period, irrespective of order, and 
also at each time point, irrespective of treatment, to look for an order effect. The 
mean of the 3 albumin and B2-microglobulin excretion rates at each time point was 
calculated to allow for day-to-day variation. Albumin and B2-microglobulin excretion 
rates were log transformed before analysis to correct for skewed distribution. The 
differences within and between the groups was assessed by paired or unpaired Student’s 
t test, with correction for multiple testing (112). Results are expressed as mean 
(range).
7.3 Results
Analysis for the results of each time point revealed no order effect in any variable. 
Albumin excretion rates were similar after 1 month’s treatment with bromhexine or 
placebo in all 3 groups (Table 19 and Figure 28). Similarly, other measures of renal 
function were not different between treatment periods (Table 19). The other variables 
of blood pressure and blood glucose known to effect albumin excretion remained 
constant in all 3 groups throughout the study (Table 20 and Figure 29). A tablet count 
revealed that patients had taken 97.3 (84.9-100)% of bromhexine and 95.5(93.7-100)% 
of placebo tablets. No adverse effects of treatment were noted.
7.4 Discussion
No effect of treatm ent with bromhexine 72 mg daily for one month on albumin 
excretion or any other measure of glomerular or renal tubular function in IDDM 
patients with varying degrees of albuminuria has been demonstrated. Nor was there 
any change in blood glucose control or blood pressure, variables which by themselves 
alter albumin excretion. The hallmark of diabetic nephropathy is accumulation of 
abnormal glycoproteins in the basement membrane and mesangium(62,65), reducing the 
glomerular filtration surface, with a strong correlation of glomerular filtration rate and
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Figure 28 Albumin excretion rates in 21 IDDM patients after one month’s treatment 
with bromhexine or placebo.
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Figure 29 Laboratory read capillary blood glucose concentrations after one months 
treatment with bromhexine (•—•) and placebo (o-«o). Mean (SD).
filtration surface per nephron(63). It might be expected that bromhexine, by its 
mucolytic action on glycoprotein metabolism, might reduce glycoprotein deposition in 
the glomerulus, increasing the available filtration surface and improving kidney 
function. Previous work has shown a decrease in carbohydrate-containing materials in 
diabetic patients after one months therapy with an identical dose of bromhexine(67). 
However, albumin excretion was not measured and the patients may all have had 
normal renal function. It may be that albumin excretion elevated above normal 
represents irreversible structural damage in IDDM, hence bromhexine would have no 
influence on albumin excretion. It has been suggested that another major determinant 
of album in excretion in IDDM is the loss of anionic charge on the basem ent 
membrane, perhaps due to loss of heparan-sulphate proteoglycan, rather than actual 
accumulation of glycoprotein(66). If bromhexine was ineffective in increasing anionic 
change on the basement membrane, no effect would be seen on albumin excretion.
In experimental diabetes, bromhexine has been shown to significantly decrease 
glomerular volume, with trends towards reduction of basement membrane thickening 
and kidney volume(68). The lack of effect on albumin excretion of one months 
treatment with bromhexine 72 mg daily in IDDM patients with varying degrees of 
albuminuria demonstrated here is thus disappointing.
101
CHAPTER 8
Relationship of urinary albumin excretion to the excretion of human epidermal growth
factor
8.1 Aims
Neither the cause of the whole kidney enlargement in early diabetes nor of the later 
mesangial expansion has been fully elucidated. It is possible that growth factors have 
some role in these processes. The study examines the pattern of hEGF excretion in 
healthy subjects and in diabetic patients with varying degrees of albuminuria.
8.2 Methods 
Subjects
Nineteen healthy subjects, 11 male and 8 female, (group 1) and fifty five diabetic 
patients, 29 male and 26 female, were studied. The patients were divided into 3 
groups on the basis of albumin excretion rate (AER).
Group 2 : normoalbuminuria; AER ^10.5 ^ ig/min 
Group 3 : at-risk microalbuminuria; AER 30-150^ig/min 
Group 4 : macroalbuminuria; AER >150^ig/min
The characteristics of the patients in each group are shown in Table 21. No subject
had a history of malignant or thyroid disease.
Data from patients with IDDM and NIDDM were analysed together because of the small
numbers.
Laboratory methods
Each subject collected one timed overnight urine sample for determination of albumin, 
hEGF and creatinine. AER was calculated from the duration and volume of the urine 
collection. The urinary hEGF:creatinine ratio was calculated in an attempt to relate 
hEGF excretion to renal function.
Statistical analysis
AER values were logarithmically transformed before analysis to correct for skewed 
distribution. The significance of differences between mean values was assessed by 
Student’s t test and correlations by Pearson correlation coefficient.
8.3 Results
There was a wide range in hEGF excretion from 0.20 to 11.8 nmol/1 in the total 
population studied. There was no significant difference in hEGF between the sexes in
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NORMAL
GROUP GROUP
1 2
DIABETIC
GROUP GROUP
3 4
AER £pg/min) <10.5 <10.5 30-150 >150
Number 19 18 19 18
Sex (M:F) 11:8 4:14 12:7 10.8
Age (years) 30 60*** 50*** 58***
(23-47) (29-74) (23-74) (28-77)
Duration diabetes 6 131 122
(years) (1-29) (1-29) (1-32)
HBAj (%) 9.7
(6.7-15.8)
9.5
(7.0-12.0)
9.5
(6.5-11.7)
Systolic BP 144 136 1592
(mm Hg) (100-190) (105-200) (110- 220)
Diastolic BP 84 80 892
(mm Hg) (60-100) (65-95) (80-100)
IDDM:NIDDM 4:14 10:9 8:10
Mean (range)
*** pcO.OOl versus non-diabetic group 
* p<0.05 group 3 versus 2
'y
p<0.05 group 4 versus 2
Table 21 Epidermal growth factor excretion and albuminuria: Characteristics of 
subjects studied.
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the whole population or in any of the individual groups studied. Diabetic patients had 
significantly lower hEGF values than controls, regardless of albumin excretion rate 
(Table 22). There was no difference in urine creatinine concentrations in males 
compared to females in any of the groups studied. However, creatinine concentrations 
were lower in all 3 diabetic groups compared to group 1 (Table 22). There was no 
difference in creatinine concentrations between the diabetic groups.
Albumin excretion rates were significantly higher in normal males than females 
[4.8(2.5-6.9) versus 2.6(1.6-9.7)^lg/min; p<0.01]. However, no influence of sex on 
AER was seen in any of the diabetic groups. As expected, AER in group 1 was 
similar to group 2, with significantly higher values in groups 3 and 4 (Table 22).
The hEGF:creatinine ratio was similar in males and females in all the groups. Subjects 
in groups 1 and 2 had similar ratios, but those in groups 3 and 4 had significantly 
lower ratios than in groups 1 and 2 (pcO.OOl for both) and group 4 was significantly 
d iffe ren t from  group 3 (pcO.OOl; Table 22). There was a sign ifican t inverse 
correlation between hEGF:creatinine ratio and AER in the diabetic patients (r=-0.49, 
p=0.02, Figure 30). U rinary hEGF excretion correlated powerfully with urinary 
creatinine in the normal (r=0.84, pcO.OOl) and the diabetic population (r=0.91, 
p<0.001, Figure 31). There was no relation of hEGF or hEGF:creatinine ratio to age.
8.4 Discussion
Urinary hEGF:creatinine ratios are decreased in diabetic patients with pathological 
albuminuria, the decrease being related to the degree of albuminuria. The hEGF 
concentration in the overnight urine collections varied considerably, probably due to 
differences in urine volume and solute concentrations. It was thus necessary to express 
hEGF excretion in terms of urinary creatinine excretion. The ratio of hEGF to 
creatinine has previously been used as an index of urinary hEGF excretion(113). The 
present results confirm those from a previous study showing a reduced EGFrcreatinine 
ratio in end-stage diabetic nephropathy(114) and extend the observation to patients 
with lesser degrees of renal impairment.
Reduction of hEGF excretion may be explained either by decreased glomerular 
filtration or by impaired renal tubular synthesis or excretion. With a molecular weight 
of approximately 6000 daltons, one tenth that of albumin, hEGF appears freely in the
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NORMAL DIABETIC
GROUP GROUP GROUP GROUP 
1 2  3 4
ttt
AER 
pug/min)
Creatinine 
(mmol/1)
hEGF 
(nmol/1)
hEGF/creatinine 
(nmol/mmol)
Mean (range)
+++,+: p<0.001, p
*** pcO.OOl versus group 2 
pcO.OOl versus group 3
Table 22 Albumin, hEGF and creatinine excretion in normal subjects (group 1) and 
diabetic patients with normal albumin excretion (group 2), 
microalbuminuria (group 3) and macroalbuminuria (group 4)
3.7 3.5 75.2+++ 289.5+++
(1.6-9.7) (1.4-9.8) (30.0-127.9) (169-879)
7.5 3.1+++ 5.0+ 4.7
(2.5-14.7) (0.8-9.8) (0.8-13.0) (0.9-14.3)
4.5 1.9+++ 2.6+++ 2.1+++
(1.5-11.8) (0.3-4.9) (0.3-7.6) (0.1-7.1)
0.69 0.60 0.47+$? 0.38$$+*
(0.47-1.27) (0.16-1.36) (0.10-0.83) (0.10-0.63)
>c0.05 versus group 1
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urine. Severe impairment of glomerular function will thus be necessary to cause 
appreciable changes in hEGF filtration. Although by definition, our microalbuminuric 
patients excreted only small quantities of albumin, they may nonetheless have 
considerable glomerular functional abnormalities, accounting for the demonstrated 
changes in EGF excretion. Creatinine is also filtered freely by the glomerulus . The 
strong correlation of urinary hEGF and creatinine concentrations shown here may 
reflect similar defects in glomerular function.
Previous work suggests that urinary hEGF is also of renal tubular origin. It may be 
that hEGF molecules destined for excretion are abnormally internalised into renal 
tissue, possibly under the influence of hyperinsulinaemia in some diabetic patients 
(115). Internalised hEGF degradation products may conceivably serve as a stimulus 
for the development of glomerulosclerosis. An alternative explanation is that the 
synthesis of hEGF is impaired in diabetic nephropathy. The role of the kidney in the 
metabolism of EGF is not completely understood. Studies performed in mice after 
surgical removal of the salivary glands led to the suggestion that mouse kidney may be 
a site of EGF synthesis(77). The kidney is also thought to be the source of EGF in rat 
urine(76). EGF can be visualised in the distal tubular cells by immunohistochemical 
techniques(116,117) and studies using mRNA probes for mouse prepro-EGF have 
localised synthesis of this precursor to the distal renal tubule(77). Harata and 
Orth(118) have assayed for hEGF in several human tissues and found the highest 
concentration in idney homogenates. It could thus be speculated that mechanisms 
involving the synthesis or processing of hEGF from precursor molecules in the renal 
tubules might be impaired early in diabetic nephropathy, although it is generally 
thought that renal tubular function remains normal until very late in the disease 
process.
In the mouse, the release of stored EGF is stimulated by adrenergic agents(119). 
Autonomic neuropathy may thus be expected to influence the amount of EGF excreted 
in body fluids(120). However, none of the patients in this present study had clinical 
evidence of diabetic autonomic neuropathy.
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In conclusion, an inverse relationship between album inuria and urinary hEGF 
excretion in a population of diabetic patients with normal and declining renal function 
has been demonstrated. The reasons for this finding are not clear but the possible role 
of growth factors in nephropathy deserves closer scrutiny. However, our data do not 
support the hypothesis that the increased kidney size seen in early diabetic nephropathy 
is due to excessive amounts of EGF.
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CHAPTER 9
Screening for early diabetic nephropathy : the value of the albumin:creatinine ratio
9.1 Aims
Collection of an overnight urine sample for measurement of AER is tedious for the 
patient and cumbersome for the laboratory. In addition, there may be errors in the 
collection or timing of the sample. The value of an albumimcreatinine ratio measured 
on an aliquot of the early morning urine has therefore been investigated.
9.2 Methods
Timed overnight urine samoles were collected from 129 diabetic oatients (67 insulin-dependent 
and 62 non-insulin dependent). Albumin concentration _ _
and creatinine were measured as described previously and AER ^ig/m in) and 
album inrcreatinine ratio  (m g/m m ol) calculated. The ab ility  of an album in 
concentration >20 ^ ig/ml and of albuminrcreatinine ratios of >3.5 and >4.5 to predict "at 
risk" microalbuminuria (AER 30-150^jag/min) was examined.
9.3 Results
The measured albumin concentration ranged from 0.38 to 212 ug/ml (median 30.5 
^Ug/ml) in the 129 urine samples. Forty six patients had AER values between 30 and 
150 ug/min and thus were at risk of developing clinical nephropathy.
Using an albumin concentration >20 ^g/m l to predict an AER >30^ig/min, there were 
22 false positives, giving a sensitivity of 91% and specificity 73.5%. Table 23 indicates 
the corresponding results using an albuminrcreatinine ratio of >3.5 as an arbitrary cut­
off. Sensitivity was 98% and specificity 69%. If the ratio is increased to 4.5, two 
patients would have given a false negative result, the sensitivity being 96% and 
specificity 80%.
9.4 Discussion
A suitable screening test, which may perhaps need to be repeated at regular intervals, 
must have a high sensitivity and specificity and be convenient for both patients and 
laboratory staff. The results presented above support those of Gatling et al(121) that 
simple measurement of albumin concentration in an aliquot of first morning urine is 
not sufficiently sensitive to use as a predictor of future diabetic nephropathy. An 
albumimcreatinine ratio >3.5, measured on an aliquot of overnight urine,is a sensitive
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predictor of AER >30/pg/min, but only at the expense of generating a large number of 
false positives, placing an extra load on patients and the laboratory. In a diabetic 
clinic caring for 500 insulin-dependent patients, 50 might be expected to have AER in 
the range of 30-150^jig/min. Using an albuminrcreatinine ratio cut-off of 3.5 in a first 
morning urine aliquot as initial screening, 190 patients would be recalled to provide a 
timed overnight sample. Of these, 49 would be true positives and one positive would 
be missed. If the cut-off was increased to 4.5, 140 timed overnight samples would be 
necessary, generating 48 true positives and 2 false negatives. The above population was 
selected to contain a large number of patients with high AER. The false positive rate 
may therefore be exaggerated. The price of the improved specificity with the 4.5 cut­
off is decreasing sensitivity. For this reason, the most useful albumimcreatinine ratio 
cu t-off is 3.5, although a larger study would confirm this. Although 38% of the 
patients would be asked to submit a timed overnight urine sample, compliance would 
be high, in the knowledge that they might be at risk of developing renal disease.
Our uncertainty of the time-course of development of diabetic nephropathy and the 
day-to-day variation in albumin excretion in individual diabetic pa tien ts(105 ,lll) 
suggest that it may be necessary to screen diabetic subjects at regular intervals, perhaps 
once every six months, until persistent microalbuminuria develops. It is thus especially 
important that the test used is acceptable to patient and laboratory. An aliquot of the 
first morning urine passed is simple and convenient for the patient to provide and easy 
for the laboratory to handle. Many patients already bring such a specimen to the 
diabetic clinic. Urine creatinine concentrations can be quickly measured by the 
autoanalyser and in an average-sized diabetic clinic no more than one albumin assay 
would be required per week.
I therefore suggest than an albuminrcreatinine ratio measured in an aliquot of the first 
morning urine would provide an initial screening test for those at risk of developing 
clinical diabetic nephropathy. Formal measurement of AER is then necessary on all 
those screening positive to identify those with microalbuminuria.
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CHAPTER 10
Evaluation of rapid techniques for albumin measurement
10.1 Aims
It seems likely that the detection and monitoring of low levels of albuminuria will 
become a routine requirement in the diabetic clinic. Simple, reproducible but accurate 
methods are required to allow the throughput of large numbers of samples. A new 
reagent tablet, Microbumintest (Ames Limited, Stoke Poges, Slough, UK) for detection 
of urine albumin concentrations >40 ^lg/ml, and a commercial kit using an automated 
immunoturbidimetric method (Urin-Pak, Ames Limited, Stoke Poges, Slough, UK) 
have been evaluated.
10.2 Microbumintest
(a) Chemical principle
M icrobum intest reagent tablets consist of a cellulose base im pregnated w ith 
bromophenol blue and salicylic acid. One drop of urine is placed on the tablet, protein 
in the sample being adsorbed to the tablet surface. Following the addition of 2 drops 
of water, the urine is washed through the tablet but the protein remains on the surface 
where it reacts with the indicator bromophenol blue to produce a bluish-green colour. 
Results are compared with the colour chart provided by the manufacturers as:
1. negative - no colour change
2. borderline - weak colour change
3. positive - strong colour change
The manufacturers claim that samples classified 2 or 3 have an albumin concentration 
>40^ig/ml.
(b) Methods
Urine samples were obtained from 106 diabetic patients. There were 54 overnight 
collections and 52 early morning urine samples (EMU). All were Albustix negative. 
Each sample was tested by one observer in batches of 12. Twenty-four samples were 
tested independently by 8 observers on 2 occasions. One low (5.2^ig/ml) and one high 
(150^ig/ml) reference samples were tested as quality controls in each batch. The 
a lbum in con cen tra tio n  in each u rine  sam ple was also d e te rm in ed  by 
radioimmunoassay.
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(c) Results
The mean albumin concentration was 34.5 (range 1.5-149) ^ug/min in all samples, 36.1 
(1.5-149) in the overnight collections and 33.0 (2.5-145) in the EMU samples.
The Microbumintest categorisation of these 106 samples by the single observer is shown 
in Table 24 and Figure 32. If only category 3 results were considered to indicate an 
albumin concentration >40 ^pg/ml, the sensitivity of the test was 30% and specificity 
98%. When both categories 2 and 3 were considered positive, the sensitivity was 84% 
and specificity 80%.
When 8 operators tested 24 urine samples, only 81 out of 192 (42%) samples were 
correctly classified. There was complete agreement by all 8 testers in only 8 samples, 
by 7 testers in 2 samples and 6 testers in 3 samples. When each operator assayed each 
sample twice, there were 37 out of 192 (19%) changes of category, with a mean 
number of changes per tester of 4.5 (range 1-8).
(d) Discussion
The very high false negative rate and the large inter- and intra-operator variability 
make Microbumintest unsuitable for routine screening for microalbuminuria. The 
results are reminiscent of the low sensitivity and lack of precision seen with the use of 
Albustix in a clinic situation(122). 0 n e  explanationfor thelow specificityw lsensitivity 
may be that Microbumintest is not specific fo r ; albumin, but may also react with other urinary
proteins present invariable amounts in different urine; samples.
10.3 Urin-Pak I r
j ;
(a) Assay principle
This immunoturbidimetric kit uses goat anti-human albumin antibody and precipitation 
by 40g/l polyethylene glycol in 50 mmol/1 Tris buffer, pH7.0. The standard solutions 
are prepared from human albumin in physiological saline. The analysis is performed 
on the automatic Cobas Bio centrifugal analyser (Roche UK, Welwyn Garden City, 
Herts, UK). The programmable settings for the instrument are shown in Table 25.
(b) Methods
The 106 urine samples used in the evaluation of Microbumintest, described above, were 
also assayed by reference radioimmunoassay and Urin-Pak.
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Albumin Concentration
^g/m l)
Microbumintest Category 
1 2 3
Table 24
<<40 45 10 1
>40 8 27 15
Categorisation of 106 urine samples by Microbumintest.
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Figure 32 Categorisation of 106 urine samples by Microbumintest
# overnight urine sample o early morning urine sample
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Standard curve
Temperature
Wavelength
Sample volume
Reaction time
0 -1 6 0 ^ug/ml
25°C
340 nm
25^1
300 sec
Table 25 Evaluation of Urin-Pak: Programmable variables for centrifugal analyser.
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Four samples, concentration range 5.2-155.0^ig/ml, were assayed six times in each 
assay for determination of the intra-assay coefficient of variation and also in each of 6 
assays for determ ination of the inter-assay CV. Six solutions of known albumin 
concentration (range 5-160 ^ig/ml) were prepared in diluent buffer for estimation of 
recoveries. The stability of diluted standards was checked by storing prepared 
standards at 4°C for 16 days. Fourteen samples, albumin concentration range 5.2-151.2 
^ g /m l, were assayed using the stored standards at intervals from days 0-16.
(c) Statistical methods
Comparison of the methods was by Pearson correlation coefficient. Assay variability 
was assessed by the coefficient of variation.
(d) Results
Albumin concentrations as measured by the reference method are given in Table 26. 
The correlation of the two methods is shown in Figure 33. In twelve samples, the 
U rin-Pak albumin concentration was <5^ug/ml and in eight >160^ug/ml. A fter 
exclusion of these 20 samples, the correlation coefficient was 0.91 (pcO.OOl) with a 
regression equation of:-
log albumin^jrjn_pa^ = 1.02 log albumin ria"0-078
Correlation coefficients for the overnight and EMU samples were similar (r=0.92 and 
r=0.90 respectively). However, 24 of the 86 samples (28%) lay outside ±20% of the line 
of identity (Figure 33). On repeat assay of these samples, the mean percent change in 
the albumin concentration was 1.1% (range -56 - +44) by reference method and -4.8 
(range -68 - +33) by Urin-Pak and all remained outside ±20% of the line of identity.
The intra and inter assay coefficients of variation are shown in Table 26. These were 
6.2% or less at all concentrations. The mean recovery was 96.5% (range 89.7 - 100.3). 
The change in albumin concentrations in samples measured by stored standard solutions 
over a 16 day interval is shown in Figure 34. The mean percent change in the albumin 
concentrations from day 0 to 16 was -5.1% (range -23.9 - +5.1).
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Figure 33 Comparison of albumin measurements in overnight (#  ) and early 
morning urine samples ( o  ) by Urin-Pak and radioimmunosassy. 
 y = x
 ±20% of line of identity
r=0.91
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Albumin Concentration
pug/ml)
Coefficient of Variation 
(%)
Table 26
Intra-assay Inter-assay
5.6 2.3 5.1
12.5 1.3 6.2
40.7 5.2 5.2
155.0 3.0 3.2
Evaluation of Urin-Pak: intra and inter-assay coefficient of variation at 4 
albumin concentrations
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Figure 34 Evaluation of Urin-Pak: effect of storage of diluted standard 
solutions for up to 16 days.
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(e) Discussion
Urin-Pak proved to be a rapid and easy to use method for measurement of urine 
albumin. Although the overall correlation with the reference method was acceptable, 
the number of samples outside ±20% of the line of identity is worrying. The low 
percentage change on repeat assay of these samples by both methods suggests a true 
assay difference rather than an analytical error. It may be that some additional factor 
such as urine pH or solute concentration is exerting a consistent effect in one or other 
assay.
Standard solutions appear stable when stored diluted at 4°C for at least 16 days, 
reducing reagent wastage and assay cost. Recoveries were acceptable and assay 
variation small. Overnight and EMU samples behaved similarly in the assay.
In conclusion, U rin -P ak  is a quick, easy to use and precise m ethod fo r the 
determ ination of low concentrations of urine albumin. However the consistent 
difference in albumin concentration in some samples in the new and reference method 
requires further investigation.
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CHAPTER 11
Conclusions
11.1 Prevalence of abnormal albumin excretion
In 1 0 6  healthy adults, the upper limit of normal albumin excretion rate in a timed 
overnight urine collection was 1 0 . 5 yUg/min. In an unselected ou t-patien t clinic 
population, 2 2 .3 %  of IDDM patients and 3 3 .6 %  of NIDDM patients had excretion rates 
outwith the normal range. Seven percent of IDDM subjects had AER 3 0 - 1 5 0 ^lg/min 
and 5 %  > 1 5 0  ^g/m in; the corresponding figures for NIDDM were 1 0 %  and 6 % .  The 
prevalence of microalbuminuria in this population agrees well with other recently 
pub lished  E nglish  s tu d ies(9 7 ,1 2 3 ) bu t is less than  in several S candinav ian  
studies(47,95,96,124,125). Similarly, the prevalence of AER > 1 5 0 ^g /m in  is also less 
than recorded in other recent series(51,126). Some of this variation is undoubtedly 
due to differences in methodology and some may be due to real differences between 
populations: Asian(127), Indian(128), A fro-Caribbean(99) and American black 
people(129) may be at higher risk of diabetic nephropathy. However, the true 
incidence of diabetic nephropathy, at least in IDDM, may also be declining(8,21,130).
The belief that end-stage renal disease is less common in NIDDM than IDDM patients 
has been challenged recently by evidence from studies of Pima Indians. After 2 0  years 
duration of diabetes, this group has a cumulative incidence of 4 0 . 8  cases per 1 0 0 0  
person-years(131), a rate similar to insulin-dependent patients of similar diabetes 
duration followed at the Joslin clinic(21). Duration of diabetes was a strong risk factor 
for ESRD, suggesting that the much higher rate of ESRD compared with other NIDDM 
groups may be because diabetes occurs at an earlier age in Pima Indians. An 
alternative explanation is that Pima Indians carry a particular susceptibility to diabetic 
nephropathy as well as to diabetes. In keeping with the high incidence of ESRF, there 
is also a high incidence of proteinuria, also as high as in IDDM patients(132).
11.2 The associated features of abnormal albumin excretion
In IDDM, abnormal albumin excretion is associated with male sex and the presence of 
retinopathy, whilst in NIDDM the concomitant features are higher systolic blood 
pressure, retinopathy and peripheral vascular disease. A preponderance of males has 
long been a recognised feature of nephropathy and a recent study has shown an excess 
of males with microalbuminuria(123). Similarly, whilst retinopathy has been well- 
recognised as a common, perhaps even an obligatory, feature of end-stage renal
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disease, it is now accepted also as a feature of microalbuminuria(96,133). Given that 
persistent proteinuria in NIDDM has recently been shown to carry the same risk of 
increased mortality from renal and cardiovascular disease as in IDDM(134) it is 
perhaps not surprising that in this survey, abnormal albumin excretion was associated 
with peripheral vascular disease and higher blood pressure. A recent study has shown 
a significant association between albumin excretion and coronary artery disease in 
NIDDM(135). However, in a 15 year follow-up of non-diabetic and diabetic men in 
the W hitehall study, although diabetic men carried  a much higher risk of 
cardiovascular mortality, there was no significant relationship between the relative risk 
and duration of diabetes(136). This prompted the authors to suggest an associating 
link, perhaps genetic, between the two conditions, rather than a causal relationship.
The value of microalbuminuria and macroproteinuria as predictors o f cardiovascular 
mortality in IDDM(137) and NIDDM(133) have both been further emphasised recently: 
Why should diabetic nephropathy and generalised cardiovascular disease be associated?
In 1953, Lundbaek suggested that they were alternative expressions of a generalised
specific diabetic angiopathy(l). Albuminuria may simply represent a generalised
increase in the transcapillary escape rate of albumin, shown to be elevated in IDDM
patients with microangiopathy and with hypertension but no microangiopathy(138).
The transcapillary escape rate is increased in IDDM patients with m icro- and
macroproteinuria(139) and can be altered by changes in diabetic control(140). An
increased passage of albumin and possibly other molecules into arterial walls may
increase the atherogenic process(141).
One group has hypothesised that inheritance of abnormal enzymes in the extracellular 
matrix, coupled to the presence of diabetes, is responsible for both albuminuria and 
widespread vascular damage(142)
An alternative explanation of the association is of blood lipid disturbances. Blood lipid 
levels are elevated in end-stage renal disease(143). However, recent studies on IDDM 
patients with persistent proteinuria but not renal failure, have shown abnormalities in 
lipid levels compared to matched normoalbuminuric populations(144,145,146) and two 
studies have in addition shown increased lipid levels in the microalbuminuric range 
(146,147). In a study of carefully matched patients with and without nephropathy, the 
only differences found were higher blood pressure and serum cholesterol in those with 
nephropathy (148).
It is noteworthy that the Framingham study revealed an increased mortality in subjects 
with proteinuria, although numbers were too small to study separately those without 
diabetes, hypertension or heart failure(149). Recently, microalbuminuria in non­
diabetic subjects has been shown to be associated with coronary heart disease and 
peripheral vascular disease(150).
11.3 Variation in albumin excretion
This study has demonstrated a large day-to-day variation in albumin excretion in 
normal subjects and diabetic patients with all degrees of albuminuria. Several studies 
have recently confirmed this in normal children(151) and normal and diabetic 
adults(152,153) and one has suggested that the variance is greater in diabetic 
subjects(153). Calculation of the albumin:creatinine ratio did not reduce the variability 
of the overnight collection(152).
A g reat v a ria tio n  in ra te  of change over a longer period  o f tim e in both  
normoalbuminuric and microalbuminuric patients has been demonstrated here. Several 
recently published studies have shown a rather slow overall rate of change in albumin 
excretion, some patients remaining at their baseline level, some fluctuating between 
categories and only a few exhibiting steady progression(ll 1,154,155). This marked 
day-to-day variation and longer-term variability implies that no patient should be 
categorised on the basis of one measurement of albumin excretion. In intervention 
trials, adequate controls must be included since no assumptions about the rate of 
change of albumin excretion can be made.
11.4 Bromhexine and albumin excretion
No effect of one month’s treatment with bromhexine on albumin excretion has been 
demonstrated. It remains to be seen whether longer therapy will be effective. 
Glycoprotein accumulated in the basement membrane and mesangium is not static. In 
experimental animals, correction of the diabetic state by islet cell transplantation or 
insulin treatment results in improvement of the basement membrane and mesangial 
lesions(156,157).
11.5 Screening for microalbuminuria
Measurement of the albumin:creatinine ratio in an early morning sample of urine has 
been shown to be a good predictor of an elevated AER in a timed overnight urine
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sample. In children, an albumin concentration >20^ig/ml in a first morning urine 
sample has been shown to correlate well with 24h urinary albumin excretion(158). 
Using an albumin:creatinine ratio did not improve the relationship. In adults, a further 
study has shown that both a timed overnight and morning albumin excretion rate have 
high specific ity  and sensitiv ity  in predicting  a 24h excretion rate  of 20-200 
^ig/min(159). The sensitivity and specificity were further improved by use of an 
AER:creatinine ratio.
It thus seems that a timed collection may not be necessary as an initial screening test 
for microalbuminuria. Measurement of the albumin:excretion ratio in an early morning 
urine sample may have sufficient sensitivity and specificity.
There may be occasions on which a semi-quantitative screening test is deemed suitable. 
Microbumintest, evaluated here, is not suitable because of its poor discrimination and 
large intra- and inter-operator variability. The low specificity of this test has recently 
been confirmed(160). The latex bead immunoagglutination tests recently described 
appear to be easy to use, sp ec ific  fo r hum an album in  and have high 
sensitivity(161,162,163).
11.6 The future
Long-term natural history studies examining the rate of progression from normo- to 
microalbuminuria and from micro- to m acroproteinuria are required, along with 
detailed clinical studies in an effort to try to categorise those patients in whom 
microalbuminuria will develop. Thereafter, ways of decreasing the excess risk of 
cardiovascular and renal disease carried by patients with microalbuminuria should be 
explored. The main avenues appear to be control of blood pressure and blood glucose, 
and reduced dietary protein intake.
(a) Blood pressure
In this study, systolic blood pressure was related in multiple regression analysis to AER 
in NIDDM, and in univariate analysis in IDDM. Other studies have shown elevated 
blood pressure in IDDM patients with microalbuminuria(37,47,164). It is noteworthy 
that these patients do not have hypertension by any formal definition. Only when 
matched with an appropriate peer-group is the elevated blood pressure obvious(165). 
Antihypertensive therapy reduces microalbuminuria acutely(166) and a carefully
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controlled trial has shown sustained reduction in albuminuria for 1 year(167,168). An 
uncontrolled trial has shown sustained reduction in albumin excretion and a slight fall 
in GFR over 5 years(169). A long-term, randomised, properly controlled trial is 
needed. Additionally, antihypertensive therapy reduced the transcapillary escape rate of 
albumin both acutely(170) and in the long-term(171) and thus may reduce the risk 
also of vascular disease.
It has been suggested that angiotension-converting enzyme inhibitors may offer an 
advantage over other antihypertensive therapy by selectively reducing intra-glomerular 
pressure in macroproteinuric(172,173,174) and microproteinuric patients(167). A 
comparison of antihypertensive regimens in micro- and macroalbuminuria is required.
A short-term  study comparing the effects of an angiotensin converting enzyme 
inhibitor and a calcium antagonist found similar hypotensive action without alteration 
in renal blood flow, GFR and filtration fraction(17/). The albumin excretion rate and 
fractional clearance of albumin were reduced to a similar extent by both drugs.
Animal studies have demonstrated that the angiotensin converting enzyme inhibitor 
enalapril retards the development of glomerular basement membrane thickening and 
reduces albumin excretion in diabetic, spontaneously hypertensive and diabetic and 
hypertensive rats(176).
The generally accepted view until recently was that hypertension was a consequence of 
rather than cause of diabetic nephropathy. However, the demonstration of elevated 
blood pressures very early in the course of the disease challenged this assumption. 
Viberti studied parents of IDDM patients with and without nephropathy(177). Blood 
pressure was higher in the parents of the patients with nephropathy. They further 
found that the rates of sodium-lithium countertransport in red blood cells, a marker 
for essential hypertension and whose activity is genetically determined(178) were 
higher in the group with nephropathy(179). These observations have been confirmed 
by another group(180) and a third group has demonstrated that diabetic nephropathy 
occurs in familial clusters(181). It thus seems possible that those diabetic patients at 
risk of nephropathy have inherited the predisposition to hypertension which may 
promote the development of diabetic nephropathy.
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(b) Blood Glucose Control
One randomised, controlled trial has demonstrated that albumin excretion was 
unchanged after 1 year of strict blood glucose control(182) but after 2 years, no 
patient in the strictly-controlled group had progressed to clinical nephropathy whereas 
5 out of 18 in the conventionally controlled group had progressed(183). Additionally, 
the fractional clearance of albumin had increased in the conventionally controlled 
group but not in the very well controlled group. However, this study included a 
substantial number of patients who although they had elevated albumin excretion, had 
not been shown to be at risk of progression. Also the numbers studied were rather 
small. A further trial is therefore required.
A comparison of renal histological changes in diabetic patients at least 1.9 years after 
renal transplantation with or without pancreas transplantation, showed that the 
recipients of pancreas transplants had no evidence of structural diabetic disease and 
had small glomerular volumes and less mesangial expansion compared to those receiving 
only renal transplants(184). This evidence suggests that good blood glucose control, if 
started sufficiently early in the course of diabetes, can prevent the development of 
diabetic nephropathy.
(c) Dietary Protein Restriction
Reduction of dietary protein intake to a moderate intake of 40g per day reduces 
a lbum in  ex cre tio n (1 8 5 ) and may slow the ra te  of decline in  g lom eru lar 
function(38,186,187) in IDDM patients with overt nephropathy. In patients with 
microalbuminuria, a 3 week trial of a reduced protein diet has shown reduction in 
albumin excretion and in GFR from hyperfiltration levels(188). Obviously, larger and 
longer-term studies are required in both persistent and microalbuminuria although the 
difficulties of adding protein restriction to an already limited diet are enormous.
(d) Other measures
Restoration of blood lipids to more normal levels, along with measures to improve 
blood pressure and blood glucose control, may help to reduce the high cardiovascular 
mortality in both macro- and microproteinuria. Abnormal prostaglandin production 
by the mesangium and impaired mesangial contractility to prostaglandin may have a 
role in the pathogenesis of glomerular hyperfiltration in nephropathy(189). One trial 
of a specific thromboxane inhibitor resulted in a decrease in albumin excretion in 
IDDM patients with microalbuminuria(190). Further work is required.
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The enzyme aldose reductase is the rate-limiting enzyme in the polyol pathway which 
converts glucose to its corresponding sugar alcohol sorbitol. Sorbitol accumulates in the 
glomeruli of streptozotocin diabetic rats(191) and may, by osmotic disruption or 
depletion of myo-innositol, be involved in the pathogenesis of diabetic nephropathy. 
The activity of aldose reductase has recently been shown to be increased in kidneys 
from diabetic rats(192). Inhibition of aldose reductase by sorbinil reduces glomerular 
basement membrane thickening and mesangial expansion without affecting albumin 
excretion or renal functional parameters in experimental diabetes(193). However, a 
further study using a different aldose reductase inhibitor, statil, found no effect on 
histological or functional parameters(194). The reasons for such discrepancies are not 
clear but may have resulted from differences in the inhibitor used, different duration 
and severity of diabetes and different methods of histological assessment. The use of 
aldose reductase inhibitors in the various stages of human diabetes obviously needs to 
be explored. A very recent study has suggested that aldose reductase inhibition may 
reduce albumin excretion in IDDM patients with microalbuminuria(195).
A large Danish study comparing IDDM patients who had died within 35 years of 
diagnosis of diabetes with patients who had survived for more than 40 years, found 
that the early deaths were characterised by male preponderance, poor metabolic control 
and less frequent attendance at a specialised diabetes unit(196,197). Apart obviously 
from male sex, these factors are open to intervention. Hopefully by attacking these 
factors, along with attention to the other factors described above, it will be possible to 
reduce the excess mortality from renal and cardiovascular disease in diabetic patients.
11.7 Unifying Hypothesis
In 1953 Lundbaek suggested that the long-term  manifestations of diabetes were 
different expressions of one generalised diabetic vascular disease(l). Reaven has 
recently proposed a "syndrome X" of resistance to insulin-stimulated glucose uptake 
and hyperinsulinaemia as a common underlying feature of NIDDM, hypertension and 
coronary artery disease(198). The elevated rates of sodium-lithium countertransport 
described in nephropathic diabetic patients(179,180) may provide a clue to the 
mechanisms underlying these syndromes. The sodium-lithium countertransport system 
is thought to be one mode of operation of the sodium -hydrogen antiport, which 
amongst other functions, regulates cell growth and sodium reabsorption by the 
kidney(199). It has recently been shown that fibroblasts from nephropathic diabetic
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patients have higher sodium-hydrogen transport activity and more cell growth than 
cells from non-nephropathic patients(200). Proximal renal tubular absorption of 
sodium is increased in hypertensive NIDDM patients and is associated with fasting 
hyperinsulinaemia(201). thus overactivity of the sodium-hydrogen antiport could 
explain the renal hypertrophy and renal and systemic hypertension of diabetes and 
could eventually lead to renal impairment. Overactivity of the sodium -lithium  
countertransport system is also associated with lipid abnormalities in the general 
population(202). Hyperlipidaemia may further promote renal damage(203) and may, 
in combination with systemic hypertenion and the generalised increase in vascular 
permeability observed in diabetes(142), accelerate cardiovascular disease.
It is possible that insulin resistance may play a role in the mechanism linking increased 
sodium-lithium countertransport, hypertension and hyperlipidaemia(204). Insulin 
resistance is associated with essential hypertension(205) and coronary heart 
disease(206) in the non-diabetic population. It has recently been demonstrated that in 
hypertensive, non-proteinuric IDDM patients, increased activity of the sodium- 
hydrogen antiport is associated with microalbuminuria, left ventricular hypertrophy and 
increased insulin resistance(207).
Thus the combined triggers of diabetes (insulin resistance) and increased activity of the 
sodium-hydrogen countertransport system may initiate a vicious, self-fuelling cycle of 
cell overgrowth and hyperfunction, renal and systemic hypertension, and lipid 
abnormalities which eventually culminate in the widespread vascular and renal disease 
seen in long-standing diabetes mellitus.
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SUMMARY
T h e  e f f e c t  o f  t h e  m u c o l y t i c  a g e n t  b r o m h e x i n e ,  7 2  mg d a i l y  f o r  o n e  
m o n t h ,  o n  a l b u m i n  e x c r e t i o n  i n  i n s u l i n  d e p e n d e n t  d i a b e t e s  w a s  
i n v e s t i g a t e d  i n  a d o u b l e - b l i n d ,  r a n d o m i s e d ,  p l a c e b o - c o n t r o l l e d  
s t u d y .  N i n e  p a t i e n t s  w i t h  n o r m a l  a l b u m i n  e x c r e t i o n  [ o v e r n i g h t  
a l b u m i n  e x c r e t i o n  r a t e  3 . 2  ( 2 . 1 - 8 . 8 )  ; ug  m i n - 1 ; m e a n  ( r a n g e ) ] ,  s i x  
w i t h  m i c r o a l b u m i n u r i a  [ 3 6  ( 2 2 - 9 5 )  ^ g  m i n - 1 ] a n d  s i x  w i t h  
r o a c r o a l b u m i n u r i a  [ 3 2 1  ( 2 0 1 - 1 2 1 5 )  ;ug m i n - 1 ] p a r t i c i p a t e d .  A l b u m i n  
e x c r e t i o n  w a s  s i m i l a r  a f t e r  t r e a t m e n t  w i t h  b r o m h e x i n e  a n d  p l a c e b o  
i n  a l l  3 g r o u p s  [ n o r m o a l b u m i n u r i c s  3 . 6  ( 1 . 7 - 1 3 . 5 )  v e r s u s  3 . 3  
( 1 . 9 - 1 3 . 2 )  j j g  m i n - 1 ; m i c r o a l b u m i n u r i c s  4 0  ( 2 0 - 1 2 8 )  v e r s u s  3 7  ( 2 0 -  
1 0 3 ) ;  m a c r o a l b u m i n u r i c s  3 9 6  ( 2 4 7 - 2 1 6 0 )  v e r s u s  4 4 3  ( 2 9 2 - 2 5 9 2 ) ) .  
E x c r e t i o n  o f  ^ 2 _ m i c r o 9 l o l ) u l l n  anc* p l a s m a  c r e a t i n i n e  w e r e  
i d e n t i c a l  a t  t h e  e n d  o f  e a c h  t r e a t m e n t .  B l o o d  g l u c o s e  c o n t r o l  
a n d  b l o o d  p r e s s u r e  r e m a i n e d  c o n s t a n t  t h r o u g h o u t  t h e  s t u d y  i n  t h e  
3 g r o u p s .  We c o n c l u d e  t h a t  b r o m h e x i n e  7 2  mg  d a i l y  f o r  1 m o n t h  
h a d  n o  e f f e c t  o n  a l b u m i n  e x c r e t i o n  i n  IDDM p a t i e n t s  w i t h  n o r m a l  
a n d  p a t h o l o g i c a l  a l b u m i n u r i a .
K e y  w o r d s :  B r o m h e x i n e ,  a l b u m i n  e x c r e t i o n ,  I D D M ,  d i a b e t i c  
n e p h r o p a t h y
2
INTRODUCTION
The development of nephropathy in insulin dependent diabetes (IDDM ) is marked by increasing 
urinary  album in excretion . C linical nephropathy  is defined as the developm ent o f persistent 
Albustix-positive (Ames Ltd, Stoke Poges, Slough, U K ) proteinuria (I) . Prior to the appearance 
o f persistent proteinuria, there is a stage o f increased albumin excretion above normal but short 
o f Albustix-positive proteinuria. Several studies have shown that IDDM patients exhibiting this 
so-called "microalbuminuria, later develop persistent proteinuria (2-5). The phase o f persistent 
proteinuria has proved irreversible, antihypertensive therapy simply slows the rate o f decline of 
g lom eru la r f i ltra tio n  ra th e r  th an  h alting  the d e te r io ra t io n ^ ) . It is hoped  how ever, that 
treatm ent o f the earlier stage o f  m icroalbum inuria may be more f ru itfu l. Im proved blood 
glucose control may prevent the progression to persistent proteinuria(7) and reduction in dietary 
protein has been shown to reduce albumin excretion, at least in the short-term (8).
The histological features o f diabetic nephropathy are o f increasing deposition o f glycoprotein 
and oligosaccharide m aterial in the basement membrane and m esangium (l). Accum ulation of 
such m aterial in the glom erular tu f t  may reduce the glom erular f iltra tio n  surface(9) whilst 
qualitative abnorm alities o f the oligosaccharide material may lead to loss o f  anionic charge on 
the basement membrane and enhanced passage o f  albumin(JO). The vinka alkaloid bromhexine 
is a m ucolytic agent thought to after glycoprotein synthesis. B rom hexine has been shown to 
decrease the u rin ary  excretion  o f  carbohydrate containing substances in ID D M (ll)  and to 
decrease glomerular volume in experimental diabetes(12) and this is o f potential benefit in the 
treatm ent o f diabetic nephropathy.
We have therefore examined the effect of bromhexine on albumin excretion in IDDM patients 
with varying degrees o f nephropathy.
3
METHODS
Subjects
Tw enty one IDDM patien ts were studied . They were div ided  in to  3 groups on the basis of 
overnight albunjin excretion rates in 2 out of 3 sterile, ketone-free urine collections:
G roup 1: norm oalbuminurics, AER ^10.5 } i g  min"*
Group 2: m icroalbuminurics, AER 1 0 . 6 - 1 5 0 m in '*
G roup 3: macroalbum inurics, AER >150^g  min"* ^
P atient characteristics at baseline are shown in tables 1 and 2. O ne p a tien t in g roup 3 took 
carbam azepine fo r pa in fu l periphera l neuropathy and thyroxine fo r  au to -im m u n e  thyroid 
disease, in constant dosage throughout the study. No other subject took any m edication other 
than insulin throughout the study and diet was unaltered ..
Study design
The study was a placebo-controlled, double-blind randomised trial. Subjects were randomised 
at baseline, w ithin th e ir  album in excretion  groups, to receive brom hexine 8  mg or placebo 
tablets, three tablets three times a day each for 4 weeks. There was a 2 week "wash-out" period 
between each treatm ent period when all patients took placebo tablets. Clinical and laboratory 
measurements were made at the beginning and end of each treatm ent period. Patients collected 
3 timed overnight urine samples fo r measurement o f album in, /B2 ' m *cro8 *obulin a t each time 
point. Blood was drawn for determ ination o f H bA j, s e ru m ^ 2 _m*cro8 *obulin and fructOsamine 
and plasma creatinine. Blood pressure was measured in the sitting position after 5 m inutes rest, 
using K o ro tc k o ff  phase V d ias to lic  p ressure . A tab le t cou n t w as p e rfo rm e d  to  check 
compliance. On the day prior to each clinic visit, patients perform ed 4 capillary blood glucose 
tests using BM T est G lycem ie 1-44 strips (Boehringer, M annheim , West G erm any), one test 
before each m ain meal and one before bed. The test strips w ere re tu rn ed  to an a ir- tig h t 
container and brought to hospital next day, where they were read by re flec tance  m eter. The 
study was approved by the local ethical committee and all patients gave inform ed consent.
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Laboratory analysis
Urine was collected into 0.5ml 4M NaOH and 0.5ml 0.1% merthiolate. Album in was measured 
by sing le-an tibody  radioim m unoassay(I3). The in ter-assay  co effic ien t o f  variation  (CV) was 
4.1% at 3 .5^ig ml"* and 10.0% at 125 j i g  ml- *. The upper limit o f norm al in our laboratory 
for overnight album in excretion rate is <10.5 ^jg m in '* . U rinary and serum I^-m icroglobulin  
were measured by radioimmunoassay(14). The inter-assay CV was 4.7% at 77.3 jtg  1"* for urine 
and 7.0% at 1.63 mg I"* in se ru m . G lycosy lated  haem oglobin  w as m easu red  by Corning 
electrophoresis, the normal range being 5.0-7.5%. Fructosamine was assayed by a modification 
o f the method of Johnson et al using a Cobas Bio centrifugal analyser(15). The reference range 
is 1.79-2.35 mmol fructosamine lOOg albumin"*.
Plasma creatinine was determ ined by m odified automated Ja ffe  technique. Excretion rates for 
albumin and j^ 2 "m *cr° 8 *°bu'>n were calculated from the respective u rinary  concentrations and 
the duration and volume o f the overnight urine collection.
Statistical analysis
Results were analysed at the end o f  each treatm ent period, irrespective o f  o rder and also at each 
time point, irrespective o f treatm ent, to look fo r an order effect. The mean o f  the 3 albumin 
and ^ -m ic ro g lo b u lin  excretion rates at each time point was calculated to allow fo r day-to -day  
variation. Albumin and ^ 2 m*croSiobulin excretion rates were log transform ed before analysis to 
correct fo r skew ed d istribu tion . T he d ifferences w ithin and betw een groups was assessed by 
paired or unpaired Student’s t- te s t, w ith correction for multiple testing. Results are expressed 
as mean (range).
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RESULTS
Albumin excretion rates were similar after 1 month’s treatm ent with brom hexine or placebo in 
all 3 groups [group 1: 3.6(1.7-13.5) versus 3.3(1.9-13.2); group 2: 40(21-129) versus 37.1(20-103); 
group 3: 397(2415-2160) versus 443.4(292-2593)/ug min"*; bromhexine versus placebo, Table 3 
and F igure 1], Sim ilarly , o ther m easures o f renal function  w ere not d if fe re n t betw een the 
treatment periods in each group. (Table 3). There was no change in systolic blood pressures or 
blood glucose control as judged by H b A j, fructosam ine or laboratory  read , se lf-co llected  
capillary blood glucose concentrations (Table 4 and F igure 2) th roughout the study. A tablet 
count revealed that patients had taken 97% brom hexine and 98% placebo tablets. No adverse 
effects o f treatm ent were noted
DISCUSSION
We have demonstrated no effect o f treatm ent with bromhexine 72 mg daily fo r one month on 
album in excretion  o r any o ther m easure o f  glom erular or renal tu b u la r function  in IDDM 
. patients w ith varying degrees o f  a lbum inuria . N or was there any change in blood glucose 
control or blood pressure, variables which by themselves alter albumin excretion. The hallmark 
o f diabetic nephropathy is accumulation o f abnormal glycoproteins in the basem ent membrane 
and m esangium (16), reducing the g lom erular f iltra tio n  surface, w ith  a strong  corre la tion  o f 
glom erular filtra tio n  rate  and filtra tio n  su rface  fo r nephron(9). It m igh t be expected that 
brom hexine, by  its m ucolytic action on glycoprotein  m etabolism , m ight reduce g lycoprotein 
deposition in the glomerulus, increasing the available filtration surface and im proving kidney 
function . P revious w ork has show n a decrease in the excretion o f  carbohydrate-con ta in ing  
m a te r ia ls  in  d ia b e t ic  p a t ie n ts  a f t e r  o n e  m o n th s  th e r a p y  w ith  an  id e n t ic a l  d o se  o f  
brom hexine(l 1). However, albumin excretion was not measured and the patients may all have 
had normal renal function. It may be that album in excretion elevated above normal represents 
irrev ers ib le  s tru c tu ra l dam age in ID D M , suggesting  th a t g lyco ly tic  agen ts  w ould  on ly  be 
e f fe c tiv e  as p r im a ry  p re v e n tio n , r a th e r  th a n  in th e  b reak d o w n  o f  a l r e a d y -d e p o s ite d  
glycoprotein. It may be that a longer treatm ent period is required to show changes in albumin 
as opposed to carbohydrate excretion, or that a higher dose o f brom hexine is required. It has 
been suggested that the major determ inant o f album in excretion in IDDM is the loss o f anionic 
change on the basement membrane, perhaps due to loss o f heparan-sulphateproteoglycan, rather
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than actual accum ulation o f glycoprotein(lO ). If brom hexine was in effec tu a l in increasing 
anionic change on the basement membrane, no effect would be seen on album in excretion.
In experim ental d iabetes , brom hexine has been shown to s ign ifican tly  decrease g lom eruhr 
volum e, w ith a tendency to reduce basem ent m em brane th ickening and kidney volume(12). 
However, only in those animals given a large dose (25 mg kg*^) brom hexine were significant 
changes seen.
In conclusion, we have shown no effec t on album in excretion o f  one m onths treatm ent with 
brom hexine 72 mg daily in IDDM patients with varying degrees o f album inuria.
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LEGENDS
Figure 1. A lbum in excretion rate in 21 IDDM patients with varying album in excretion at
the end o f one months treatm ent with brom hexine and placebo.
Figure 2. Laboratory read, self-collected capillary blood glucose concentrations in IDDM
patients with normoalbuminuria (lower panel), m icroalbuminuria (middle panel) 
and m acroalbum inuria (upper panel) a fter one months treatm ent with brom hexine 
( • — •)  or placebo (o— o).
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TABLE 1.  P a t i e n t  c l i n i c a l  c h a r a c t e r i s t i c s  a t  b a s e l i n e .
1
CROUP
2 3
n 9 6 6
Age 34 .7 4 7 .2 ** 3 3 .0 11
(y e a rs ) (23 -46 ) (37-54) (21 -46 )
D u ra tio n  D iabetes 15.9 22.8 23.5
(y e a rs ) (6 -2 9 ) (7 t 32) (1 9 -3 1 )
R e tinopa thy 3 :0 4 :2 3 :3
(Background : P r o l i f e r a t i v e )  
HbA, 8.1 10.6* 10 .22
(X) (6 .6 -1 0 .7 ) (8 .1 -1 3 .1 ) (8 .6 -1 1 .7 )
fru c te sa m in e 3.05 3.09 3.23
(nmol lOOg a lbum in ’ S (2 .5 5 -3 .7 8 ) (2 .6 3 -3 .5 8 ) (2 .7 9 -3 .5 6 )
S y s to l ic  b lood  p re ssu re 122 137** 141222
(mm Hg) (112-142) (118-142) (132-146)
D ia s to l ic  b lood  p re ssu re 79 81 872
(mm Hg) (72 -9 0 ) (80 -84 ) (80-94)
* , * * :  p<0.05, p < 0 .0 l,  group 1 v 2
p<0.01, group 3 v  2 
2 ' 222.- p<0.05, p < 0 .0 0 l,  group 3 v  1
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TABLE 2 .  Renal  c h a r a c t e r i s t i c s  a t  b a s e l i n e
CROUP
2
3 .2  3 6 .2 * * *
^ jg  m in '1) ( 2 .1 -8 .8 )  (2 2 .1 -9 5 .9 )
^ 2 -H ER 27 .9  68.4
(ng m in '1) (6 .6 -8 5 .2 )  (4 .0 -5 4 0 .8 )
Serum j l j - H  1.43 1.81
(mg I * 1) (1 .1 6 -1 .8 5 )  (1 .4 7 -2 .0 1 )
Serum c re a t in in e  89 87
^jjmol l ' 1) (59 -118) (68 -118 )
* * *  p<0.001, group 2 c 1 
222 p<0.001, group 3 v  1 and 2
p2-n ER p2 •m ic ro g lo b u lin  e x c re t io n  ra te
i a
(2 0 1 .9 -1 2 1 5 .9 )
33.2
(1 3 .9 -2 0 9 .8 )
1.79
(1 .4 8 -2 .0 3 )
97
(82-124)
TABLE 3. Measures o f rena l fu n c t io n  in  no rm oa lbum inuric , m ic ro a lb u m in u r ic  and m acroa lbum inuric  IDDM 
p a t ie n ts  a f te r  1 months trea tm en t w ith  bromhexine and p lacebo.
Norm oalbum inuric 
P lacebo Bromhexine
CROUP 
M ic ro a lb u m in u ric  
Placebo Bromhexine
M acroalbum inuric 
Placebo Bromhexine
tyjg m in '1)
3 .3 3 .6 37.1 443.4
(1 .9 -1 3 .2 )  (1 .7 -1 3 .5 )  (2 0 .1 -1 0 3 .3 )  (2 0 .7 -1 2 8 .6 )  (29 2 .4 -2 5 9 2 .9 ) (247 .8 -2160 .3 )
p 2 -MER 
(ng- m in *1)
2 7 .9 39.3 43 .7 53.4
(7 .5 -5 1 .3 )  (1 .4 -1 1 3 .0 )  (1 0 .6 -1 0 1 .2 )  (2 .3 -2 0 0 .6 )  (2 4 .7 -4 2 3 .3 )  (3 1 .2 -1 7 1 .8 )
Serum h H 
(mg I 1)
1.42 1.65 1.76 1.88 1.96 1.80
(1 .5 0 -1 .9 9 )  (1 .6 0 -2 .0 9 )  (1 .5 5 -2 .9 6 )  (1 .4 8 -2 .0 9 )
Serum c re a t in in e
^im ol/l )
86 85
(7 7 -1 0 8 ) (80 -103)
91 95
(78-115) (85 -115)
110
(86 -180 )
96 .
(81 -110 )
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TABLE 4. G lycaem ic c o n tro l and blood p re ssu re  a f te r  one months tre a tm e n t w ith  brom hexine o r placebo in  the 
3 groups o f p a t ie n ts .
N orm oalbum inuric 
P lacebo Bromhexine
GROUP
M icro a lb u m in u ric M acro a lbu m inu ric
P lacebo Bromhexine P lacebo Bromhexine
Fructosam ine 3 .00
(mmol 100g
2.95 3 .07  3.09 3 .3 6  3.34
album in ' )  (2 .5 5 -3 .3 4 )  (2 .4 2 -3 .3 0 )  (2 .8 1 -3 .3 0 ) (2 .6 3 -3 .5 8 ) (3 .1 9 -3 .6 0 )  (3 .1 4 -3 .5 8 )
HbA,
(X)
9 .2 10.3 9 .2
( 6 .1 -1 0 .3 )  (6 .3 -1 0 .2 )  (8 .0 -1 1 .4 )  (6 .3 -1 2 .9 )  (9 .1 -1 1 .7 )  (7 .2 -1 0 .7 )
S y s to l ic  BP 120 121
(mm Hg) (110-138) (104-142)
137 135
(124-150) (126-142)
141 143
(138 -150 ) (138-130)
D ia s to l ic  BP 78 78
(mm Hg) (7 0 -9 2 ) (70 -8 8 )
76
(60-86)
80
(70-86)
86  86 
(7 6 -9 4 ) (7 8 -9 0 )
14-
A E R
Oig/min)
P L A C E B O  B R O M H E X I N E
r
BLOOD
GLUCOSE
(mmol/I)
14
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